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Stereotactic Ablative Body Radiotherapy (SABR), when delivered to the spine with metal in
close proximity, prompts clinical concerns in treatment outcomes due to the accuracy of the
treatment given. The treatment planning system, used to estimate dose during treatment
planning, may not calculate dose accurately when metal is concerned. To date, there has been
little research testing the accuracy of RayStation’s collapsed cone convolution algorithm in
predicting dose deposition in treatments when metal is involved. The aim of this study is to
investigate the impact of metal prostheses on dose deposition predicted in RayStaioin used to
plan SABR treatments at Auckland City Hospital (ACH).
To complete this work, an anthropomorphic phantom called MattL was created and validated
for film and ionisation chamber measurements of SABR spine treatment plans. MattL is a
modular style phantom which can be altered so an ionisation chamber and film can be placed
in different locations. Additionally, different versions of MattL were created with and without
metal implants. Following the validation process, dose measurements of SABR spine treatment
plans were performed and compared to the dose calculated in RayStation on virtual models of
MattL with and without metal inside. These experimental results were used to determine if
RayStation’s calculated dose with metal is statistically equivalent to that without metal.
Results obtained in this work indicate that SABR spine treatments with metal-ware in-situ are
equivalent to spine SABR treatments without metal-ware to within ±5% uncertainty. Conse-
quently clinical treatment of SABR spine patients with metal implants close to the treatment
region may be viable at ACH. The outcome of the project has been encouraging and has shown
that MattL may be useful in testing the quality of patient specific SABR spine treatment plans,
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Cancer is a complex and terrible disease that is harder to treat if metastasised. Approximately 40 -
70% of all cancer patients are diagnosed with spinal metastasis [22] while post-mortem studies
suggest that 90% of cancer patients may have microscopic evidence of metastases [23,24]. Spinal
cancer patients presenting for radiotherapy may have metal implants in-situ due to prior conditions.
Surgical spine decompression or stabilisation may be required for treatment of musculo-skeletal
tumours of the spine, followed by radiotherapy as an adjuvant therapy for short term control and
pain palliation [23,24]. Given an aging population and increased survival rates due to improved
diagnosis and treatments [25], it is expected that an increasing number of patients with metal
stabilisation devices are seen requiring radiotherapy. Within the last year, several patients with
spinal metastases have presented for stereotactic ablative radiotherapy (SABR) with metal hardware
in-situ at Auckland City Hospital (ACH). Typically these patients have undergone surgery to
implant titanium alloy screws connected to a cobalt-chromium alloy rod in the posterior aspect of
the vertebrae, stabilising the affected section of the spinal column (figure 1.1).
Clinical software, calculates the radiation dose delivered from a treatment plan during the design of
this plan. One of the main problems with this calculation is the speed in which it is performed. A
way clinical software increases the speed of calculation is to make a number of assumptions of how
interactions in the human body occur. However, with metal, some of these assumptions may no
longer be appropriate as interactions with the human body differ compared to interactions with
metal. This thesis investigates if these assumptions result in accurately calculated dose by clinical
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Figure 1.1: Model of posterior fixation with a nail-stick implant system [1].
software when metal is within the treatment region for SABR spine treatments.
Several authors have investigated the dosimetric effects of metal via Monte Carlo simulation or
measurements [26–30,30–32]. These suggest metal introduces increased back-scatter in the area
incident to the metal. Alternative approaches have identified a reduction of dose distal from
implants by measurements of dose distributions with and without implants [33]. Further research
has verified the accuracy of algorithms in handling high atomic density materials for VMAT
radiotherapy [32,34] with only one instance of research investigating spine SABR treatments [35]. To
the best of this author’s knowledge, research investigating the dosimetric accuracy of spine SABR
treatments with the CCC dose calculation algorithm used in RayStation has not previously been
reported. As there was access to surgical grade spinal implants, clinical engineering services, devices
to measure radiation but no access to a clinically working Monte Carlo dose calculation engine, this
thesis looked at experimental measurements of radiation around metal implants in multi-beam
SABR treatments to investigate this problem. This involved the design, build and validation of a
phantom to measure the amount of radiation delivered during a treatment.
In order for the reader to completely understand the problem metal presents in radiotherapy, an
understanding of the appropriate particle physics fundamental to radiation therapy is discussed as
background, in section 2.1.1. There are many ways to generate radiation therapeutically, for example
through the insertion of a radioactive source, or from an external source of radiation such as a linear
accelerator (linac) which is commonly used in clinical radiation therapy. The linac used for SABR
treatments is briefly described in section 2.1.2. Radiotherapy treatments are optimised to maximise
the radiation damage to tumour cells while minimising damage to normal, healthy tissue. The
impact of radiation on cells and the body are described in section 2.1.3.
3
The spinal cord is one of the most important normal, healthy tissues clinicians want to minimise
damage to in SABR spine treatments. The recommended dose to the spinal cord from recent clinical
trials [36] have been considered at ACH when establishing protocols for SABR spine treatments. An
overview of spinal cancer and background on SABR spine treatments is given so the reader has some
background information on this treatment, in section 2.2.1. Additionally, the reader should
understand how treatment plans are created and how clinical software estimates the amount of
radiation delivered when metal is involved. These processes are provided in section 2.2.2. As
mentioned previously, a phantom is used in this thesis to perform radiation measurements. To create
this phantom, an understanding of phantom materials and devices to measure radiation were
required. This is given in section 3.1.3 so the reader can understand what was considered in
development of the phantom. To assess if clinical software appropriately estimates radiation for
clinical treatments of SABR spine patients with metal-ware in-situ, a statistical analysis of the
measurements made in the phantom was performed. The statistical methods described in section 2.5
helped to answer one of the main aims of this research, to determine if the clinical software used at
ACH for SABR spine treatment planning adequately estimated the amount of radiation delivered to
SABR spine patients with metal implants in the vicinity of the treatment region.
As this research progressed it became evident the project was split into two mains tasks. The first
was the design, production and validation of a phantom for radiation measurements, presented in
chapter 3. The second was the use of this phantom to measure radiation from spine SABR treatment
plans, presented in chapter 4. While the results of these tasks are presented in the aforementioned
chapters, discussion of these tasks can be found in chapter 5 as both were required to meet the aims




To fully understand the purpose of this thesis key concepts of radiation therapy used to treat spinal
cancer are described in this chapter. These include the interactions of ionising radiation with matter,
an overview of the linac typically used in SABR spine treatments and the interaction of radiation
with the body’s tissues, described in section 2.1. For some background information, an overview
spinal cancer and SABR spine treatments are given in section 2.2.1. Additionally, the development
of the treatment plan is given in section 2.2.2 so the reader can be familiar with the processes used
and investigated in this thesis. An explanation on how clinical software estimates radiation delivered
from a treatment is also given in section 2.3. This includes a description of how radiation dose in
heterogeneous materials is calculated in the software. As mentioned in chapter 1, a major part of
this thesis was the design of a phantom that facilitates the measurement of radiation. Devices used
to measure radiation and properties of materials available to make this phantom, considered during
the design process are described in section 3.1.3 so the reader understands the final design of the
phantom created. Measurements made in the phantom were statistically analysed to determine if the
accuracy of clinical software in estimating radiation delivered from SABR spine treatment plans with
metal-ware close to the treatment region is equivalent to when there is no metal-ware near the
treatment region. Statistical methods relevant to this thesis are described in section 2.5 so the reader
understands their use.
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2.1 Fundamentals of Radiation Therapy
After surgery, radiotherapy is the next most successful and frequently used modality for the
treatment of cancer [37]. So the reader understands the scope of the research presented in this thesis
we begin with an introduction to particle interactions, fundamental to radiotherapy in section 2.1.1.
The linac, a sophisticated machine typically used in clinical radiotherapy is also described for further
background in section 2.1.2. The radiotherapy treatment delivered from the linac is carefully
designed to induce maximal damage to tumour tissue while sparing healthy tissue. To do this,
clinicians consider the effect radiation has on the cells, explained in section 2.1.3 and the use of
SABR to treat spinal cancer, described in section 2.2.1. As there is variation between patients (e.g.
tumour size and individual anatomy), treatment plans are individually designed for each patient.
The planning process using clinical software that ensures a quality treatment for each patient is
described in section 2.2.2. The way in which the clinical software estimates dose is summarised in
section 2.3 and includes a description of how clinical software calculates radiation through high
density materials. Additionally, a description of statistical methods used to analyse the results of
this thesis are provided in section 2.5 so the reader can understand the basis of their use.
2.1.1 Radiation Interaction Mechanisms
In order to appreciate how radiation therapy works at the cellular level we need to understand the
interaction processes which occur between ionising particles of radiation and cell molecules. The
major photon interaction processes of interest in radiotherapy are the photoelectric effect, Compton
scattering and pair or triplet production [2].
The interaction of a photon with energy hν and a tightly bound inner orbital shell electron of an
absorber atom with binding energy EB, resulting in the ejection of this electron is called the
photoelectric effect (figure 2.1). The electron is ejected if the incident photon is completely absorbed
and has sufficient energy to liberate the electron from the atom (hν ≥ EB). The ejected electron
may have kinetic energy EK, if the incident photon energy is higher than the binding energy of the
electron ejected (EK = hν - EB).
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Figure 2.1: Schematic diagram of the photoelectric effect. An incident photon of energy hν,
interacts with a tightly bound orbital electron, resulting in the ejection of the orbital electron
from the atom with kinetic energy EK. Taken from Podgorsak [2].
The interaction of a photon of energy hν, with a loosely bound outer orbital shell electron of an
absorber atom which results in the incident photon being scattered is referred to as Compton
scattering (figure 2.2). The scatter of the incident photon is incoherent, inelastic scattering that also
results in ejection of an electron with kinetic energy EK. The maximum kinetic energy of the ejected




Figure 2.2: Schematic diagram of inelastic Compton scattering. An outer orbital ‘Compton’
electron is ejected from the atom by a high-energy incident photon, which loses energy in the
interaction and is scattered. Modified from Oldham [3].
An incident photon with energy hν exceeding 2mec
2 = 1.02 MeV, where mec is the rest energy of an
electron and positron, may result in the production of an electron-positron pair following the
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complete absorption of the photon by the absorber atom. This interaction conserves energy, charge
and momentum. This may occur from photon interaction with the Coulomb field of the atomic
nucleus or from photon interaction with an inner shell orbital electron (figure 2.3). For the latter,
some of the photon energy is absorbed by an orbital electron causing the emission of the orbital
electron in addition to the electron-positron pair. The positron will interact with atomic electrons to
produce a pair of photons.
Figure 2.3: Schematic diagram of pair production: (a) nuclear pair production through inter-
action with the Coulomb field of the absorber nucleus and (b) electron pair production (triplet
production) in the Coulomb field of an orbital electron. An incident photon of energy hν,
interacts with a tightly bound orbital electron, resulting in the ejection of the orbital electron
from the atom with kinetic energy EK. Taken from Podgorsak [2].
Another important photon interaction in radiotherapy is bremsstrahlung production. The
bremsstrahlung is an x-ray photon that results from inelastic Coulomb interactions between an
incident electron and nuclei of an absorber. The electron accelerates or decelerates near the electric
field of the absorber nuclei, causing it to scatter in a different direction while also losing kinetic
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energy due to acceleration caused by a change in motion. This lost kinetic energy is emitted in the
form of photons known as bremsstrahlung radiation (figure 2.4) [2].
Figure 2.4: A diagram depicting interaction between a charged particle and the nucleus of an
atom (radius, a) that changes the motion of the charged particle (and therefore acceleration),
resulting in the emission of an x-ray photon of energy hν, known as bremsstrahlung radiation.
Taken from Podgorsak [2].
The charged (i.e. electrons) and uncharged (i.e. photons) particles liberated in the above
interactions interact with the atoms of a materials as it traverses further through the medium. As
this occurs, it transfers energy to the material through direct or indirect ionisation. Indirect
ionisation caused by the transference of energy from an uncharged photon to the medium occurs in
two steps. The first step is the release of a charged particle by photon interactions described above.
The second step is the deposition of energy from the released charged particle to the medium
through direct Coulomb interactions with orbital electrons of the medium. For direct ionisation only
the second step occurs as charged particles have the ability to directly ionise the atoms in the media
through Coulomb interactions [2].
The energy delivered from indirectly and directly ionising radiation, dE to a given mass of material
dm is typically quantified as the absorbed dose, D through equation 2.1. This has units of J kg-1
where 1 J kg-1 is otherwise known as 1 Gray (Gy). The absorbed dose helps clinicians quantify the
amount of radiation given in a treatment and relate this to the radiobiological effects of different





When considering only the energy transferred from indirectly ionising radiation the kinetic energy
released per unit mass (kerma) is used. The kerma, defined by equation 2.2, describes the kinetic
energy transferred from an uncharged particle to a charged particle (i.e. electrons) in the medium [7].
This is another important concept to understand in radiotherapy as typically photons (i.e. uncharged
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Where ∂Etr is the average energy transferred from indirectly ionising radiation to a volume of mass,
∂m. The mass attenuation coefficient is defined by equation 2.3. The mass attenuation coefficient
µm, of a material quantifies its ability to absorb incident photons as they are transmitted through
the material, losing energy by transferring it to the material as dose. Hence, the total mass
attenuation coefficient is the sum of all individual interactions that a photon, of energy hν, may have
with the atoms of an absorber (figures 2.5 & 2.6).
µm = µ/ρm (2.3)
Where µ is the linear attenuation coefficient that describes the removal of photons from the beam
fluence and ρm is the mass density of the irradiated material. Similar to the mass attenuation
coefficient, the mass stopping power, S, describes the energy loss, of a charged particle propagating









Where dE is the energy lost from a charged particle traversing a given distance, dx. The mass
stopping power and mass scattering power (analogous to the stopping power) are considered in the
calculation of dose when a conversion of dose-to-water to dose-to-medium (or vice versa) is required,
discussed further in section 5.1.2. The International Commission on Radiation Units and
Measurements (ICRU) defines the mass scattering power T/ρ, which describes a material’s ability to







Where the multiple scattering of electrons traversing a path length l through an absorbing medium
is commonly described by the mean square angle of scattering θ2.
Figure 2.5 gives the modes of photon interactions with water that take place over a range of photon
energies. At low photon energies (< MeV), used for CT scanning and therefore calculating
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RayStation dose (explained further in section 2.2.2), the photoelectric effect dominates while at
intermediate photon energies (e.g. the range of photon energies generated in linac machines for
radiation therapy), Compton scattering dominates. At higher energies (approximately > 10 MeV),
Compton interactions start to reduce and pair production starts to dominate.
Figure 2.5: Mass attenuation coefficient against photon energy hν in the range from 1 keV to 100
MeV for water. In addition to the total attenuation, the individual coefficients for photoelectric
effect, coherent nuclear (Rayleigh) scattering, incoherent nuclear (Compton) scattering, and
pair production are also shown. Note: Rayleigh scattering plays only a secondary role in
comparison to the other coefficients. Taken from NRC [4]
Interactions in Different Materials
The predominant photon interaction over different energies for water, as depicted in figure 2.5,
differs with photon energy for other materials, e.g. lead (figure 2.6).
Figure 2.7 gives the relative dominance of the three main processes of photon interactions with
materials of different atomic number (Z) and different photon energy. At low photon energies (<
MeV), the photoelectric effect dominates for all absorber atoms and at high energies, approximately
above 10 MeV, pair production is dominant. For a material with low Z (e.g. water or soft tissue),
the range of energies at which Compton scattering dominates is broader. For water and tissue, this
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Figure 2.6: Mass attenuation coefficient µ/ρ against photon energy hν in the range from 1 keV
to 1000 MeV for lead. In addition to the total mass attenuation coefficient µ/ρ, the individual
coefficients for photoelectric effect τ , Rayleigh scattering σR, Compton scattering σC , and pair
production (including triplet production) κ, are also shown. The mass attenuation coefficient
µ/ρ is the sum of the coefficients for individual effects, i.e. µ/ρ = (τ + σR + σC + κ)/ρ. Note:
Rayleigh scattering plays only a secondary role in comparison to the other coefficients. Taken
from Podgorsak [2].
region ranges from approximately 20 keV to 20 MeV. As this is the energy range used for typical
radiotherapy treatments, Compton scattering is the most important photon interaction in
radiotherapy. However, the dominance of Compton scattering reduces for materials that vary largely
from water or tissue as pair production or photoelectric effects dominate. For higher Z materials,
there is more of a photoelectric effect at CT energies (e.g. 120 kV) then at radiotherapy linac EBRT
energies.
2.1.2 Linear Accelerator (linac)
A linear accelerator or linac, is a compact particle accelerator designed to generate ionising radiation
for use in radiotherapy (figure 2.8). The linac accelerates electrons close to the speed of light,
towards a tungsten target. On striking the target, high energy bremsstrahlung photons are
generated from the head of the linac which are directed towards the patient. The beam of photons
then interacts with the patient, depositing dose through the radiation interaction mechanisms
described in section 2.1.1. A more detailed overview of the mechanisms used in the linac to generate
high energy photons can be found in the works by Podgorsak and Mayles, and is outside the scope of
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Figure 2.7: Predominance of the three main photon interaction processes with absorber atoms
of atomic number, Z. PE: Photoelectric effect, τ ; Compton region σ; PP: Pair production κ.
Taken from Podgorsak [2].
this work [2, 7, 9]. This work focuses on the SABR treatment technique that uses a 6 megavoltage
(MV) flattening filter free (FFF) photon beam from an Elekta Versa HD linear accelerator (Elekta
AB, Stockholm, Sweden). Historically, typical external beam radiation therapy (EBRT) used a
flattened beam by utilising the flattening filter in the head of the linac (figure 2.8). However, in
recent times there is a preference towards an un-flattened, FFF photon beam as this increases the
dose rate and beam intensity predominantly near the centre of the beam (defined later in this section
as the central axis on the beam profile), which is advantageous for high dose per fraction treatment
techniques such as SABR [38]. The differences in beam intensity of the flat beam compared to the
FFF beam are evident by measuring a cross section of the beam, known as the beam profile which is
described below.
Percentage Depth Dose and Beam Profiles
In radiotherapy, the dose deposited in tissue from radiation can be characterised by the dose
deposition with depth in water as is displayed in figure 2.9. This curve is usually normalised to 100%
at the depth of maximum dose, hence the curve is commonly referred to as a percentage depth dose
(PDD) profile. Beam profiles measure the cross section of the beam, perpendicular to the direction
of beam propagation, at a given depth in a material typically water [7]. For more detail on how this
2.1. Fundamentals of Radiation Therapy 13
Figure 2.8: Configuration of a typical isocentric medical linac. The primary target, flattening
filter, collimator jaws (X and Y) and multi-leaf collimators (MLCs) sit in the head of this
machine. The flattening filter is moved out of the beam line for to generate a FFF beam
output. Taken from the RayStation v8B Reference Manual [5]
Figure 2.9: Percentage depth dose curve of a 6 MV FF (flat) and FFF photon beam. Taken
from [6].
is measured, the reader is directed to the descriptions of beam profiles from Podgorsak [7] and
guidance on beam profile measurements from Dieterich and AAPM Medical Physics Practice
Guideline 5.a [39,40]. From the beam profile, the geometric field size is defined between the 50%
14 Chapter 2. Background
relative dose levels in what is known as the penumbra region (figure 2.10). The penumbra region is
an area of steep dose gradient at the edge of the field. An example of beam profiles measured at
Figure 2.10: The field size of a beam defined as the distance between the 50% relative dose
values on the beam profile at the penumbra region, at the edge of the radiation field in an area
of steep dose fall off. Taken from Podgorsak [7]
.
various depths for a square field is given in figure 2.11. In the central region between the penumbra,
a low dose gradient or homogeneous zone is evident for a flattened beam. However, for a FFF beam,
this region is less homogeneous and peaked at the central axis (x=0).
The linac generates a FFF photon beam by removing the flattening filter at the head of the linac
from the beam line, as depicted in figure 2.8. Along the beam-line a pair of collimators jaws and
paired multi-leaf collimators (MLCs), housed in the linac head shape the beam (figure 2.8). The
collimator jaw(s) and MLCs further collimate and shaped the photon beam. Individually driven
MLCs are heavily utilised in volume modulated arc therapy (VMAT) techniques, such as the SABR
technique investigated in this study [41–43]. Typically, the photon beam is shaped to optimise dose
for maximal damage to the tumour cells while minimising damage to normal, healthy tissues. This
mechanisms of cell damage is described further in section 2.1.3.
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Figure 2.11: Examples of a 10 x 10 cm2 field size, 6 MV FF (flat) and FFF beam profile
measured at various depths in water. Taken from Baic [6].
2.1.3 Radiobiology
In section 2.1.1 we introduced the concept of dose as the deposition of energy from radiation to a
mass of given material. In radiotherapy, we are interested in radiobiology, which is the effect
radiation dose has on living tissue. On a microscopic level, radiation dose breaks the chemical bonds
of the cell’s deoxyribonucleic acid (DNA) via indirect or direct interactions (see figure 2.12). If this
cell is unable to repair this process through cellular mechanisms, programmed cell death (apoptosis)
or mitotic cell death may occur [8]. Additionally, irreparable damage to the cell’s reproductive
ability is considered just as severe as apoptosis or mitotic cell death as without the ability to
proliferate, the cell has effectively not survived to pass on DNA through cell division (reproductive
death) [8]. On a macroscopic level, the ability of a group of cells to respond and recover from
radiation damage is considered through the use of cell survival curves [8].
Cell Survival Curves
The cell survival curve is useful in understanding the impacts of radiation dose on a group of cells
(e.g. in tissue). This is important as radiation damage may cause the cell to die or the cell may be
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Figure 2.12: Damage to the chemical bonds of DNA by indirect (top) and direct (bottom)
interaction with an incident photon. Modified from Hall [8].
able to recover and survive. Lethal damage is defined as the irreversible or irreparable damage to
cellular mechanisms that inevitably lead to cell death. Conversely, sublethal damage, under normal
circumstances naturally repairs after some time. The cell survival curve depicted in figure 2.13
illustrates the fraction of cells that survive following irradiation with increasing amounts of radiation
dose [8]. The number of cells surviving is seen to decrease as the dose increases on the log plot in
figure 2.13b.
Figure 2.13: Cell survival curve on (a) a linear survival scale and (b) a logarithmic survival
scale. Taken from Mayles [9].
The cell survival curve depicts how tissue cells e.g. early and late responding tissue, respond
differently to a given amount of radiation dose (figure 2.14) [8, 9]. For late responding tissues, e.g.
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the spinal cord, the initial slope is shallow and bends more gradually as the dose increases [10,44].
Hence, late responding tissues have increased survival at low doses but significantly greater toxicity
at higher doses. For early responding tissues (e.g. tumour) the opposite is true. That is, the initial
slope of the survival curve is steep and does not bend with increased dose. The main aim in
radiotherapy is to get complete cell death of tumour tissues and minimise the cell death to normal,
healthy tissue. The predicament with this is that if we use high dose to get high tumour cell death,
we preferentially kill healthy cells but if we use low dose to spare healthy tissue, tumour cells
survive. Hence, the dose response for each tissue is considered when designing novel treatment
techniques to maximise damage to the tumour while reducing damage to vital organs in the vicinity
of the treatment region. The clinician will design the treatment by selection of the correct dose to
Figure 2.14: Dose response relationship for late-responding tissues is more curved initially, than
for early-responding tissues (e.g. tumour). This parabola tapers off with increased dose. Taken
from Mayles [10]
provide optimal tumour cell death and healthy cell survival. A common practice for this is to
prescribe a lethal radiation dose in multiple deliveries to reduce lethal damage to healthy tissues.
This practice is known as treatment fractionation and is explained through the use of the effective
cell survival curve below.
Fractionation
Conventional radiotherapy treatments are delivered over a number of treatment sessions, or
fractions [44]. The dose per fraction, number, and frequency of fractions are chosen to maximise
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tumour damage while sparing the normal tissues by allowing the repair of sublethal damage to
healthy tissue between fractions. When the treatment dose is split over many fractions to deliver a
smaller dose per treatment fraction, the cell survival curve differs from the cell survival curve for a
single treatment fraction. The resultant survival curve of the fractionated treatment is altered by
repeating the initial section of the cell survival curve that corresponds to the dose per fraction. This
is called an effective survival curve, as depicted in figure 2.15. The overall “effective” survival curve
of a fractionated treatment (on the logarithmic scale) is essentially linear from the origin. The dose
delivered per fraction is chosen to match the point at which healthy and tumour cell survival is well
separated with tumour cell survival being lower. Typically, treatment methods use 1.8 -2.2 Gy per
fraction however SABR techniques, discussed in section 2.2.1, utilise a higher dose per fraction.
Figure 2.15: The “effective” survival curve for a multi-fraction treatment compared to the cell
survival curve for a single dose treatment. In the effective survival curve, the shoulder of the
survival curve is repeated many times. Taken from Hall [8].
During the 1980s, it was found that early and late normal tissue responses are modified differently if
dose per fraction is altered from the standard 1.8 - 2.2 Gy per fraction treatment regime. This
sparked an initial interest in hyperfractionation [44]. Hyperfractionation is defined by an increased
fractionation scheme compared to the standard fractionation scheme used during a treatment course
and involves the delivery of less dose per fraction. Conversely, hypofractionation involves delivery of
higher dose per fraction as the number of fractions are reduced. There is great interest in
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hypofractionation as such treatment schemes reduce the number of hospital visits for a patient. This
is beneficial for both the patient, as less hospital visits are required to complete their treatment, and
the clinic, as it reduces time pressure on treatment machines. A change to treatments like going
from standard fractionations to a hypofractionated treatment is only clinically viable if it does not
adversely affect patient outcomes. A study by the Radiation Therapy Oncology Group clinical trial
(RTOG 0631) investigating the biological effectiveness of hypofractionation for spine metastases
treatments have shown hypofractionation is just as effective as standard fractionations methods [22].
Correspondingly, hypofractionation therapy treatment regimes such as SABR have recently been
adopted at many clinical centres, including ACH, where this thesis is based. In section 2.2, technical
aspects of SABR treatments applied to the spine region are outlined so the reader knows the process
of plan development required before clinical treatment of the SABR spine patient.
2.2 Radiotherapy Treatment
Prior to treatment, a number of steps are required to design a suitable treatment for each patient.
This involves imaging the patient, developing the treatment plan and quality assurance testing of
this treatment plan to assess if the plan, created in the treatment planning system (discussed further
in section 2.3), accurately corresponds to what is delivered on the linac unit. For better context of
planning SABR spine treatment plans, this section begins with a background on radiotherapy
treatment of spinal cancer, and describes some of the main aspects of a SABR spine treatment plan
clinicians assess to determine if the treatment plan is adequate to treat the patient.
2.2.1 Spinal Cancer and Stereotactic Ablative Body Radiotherapy
The spine is a well vascularised serial organ, closely linked to the lymphatic and venous systems.
Metastatic tumours utilise both these systems to establish themselves in distant organs.
Consequently, the most common tumours of the spine are secondary, metastatic cancers
(97%) [24,45,46]. The main symptoms for most spinal cancer patients is back pain due to epidural
compression created by the development of a soft tissue mass at the para-spinal area (figure
2.16) [23]. Additionally, spinal and neurological instability complicates the severity of this disease.
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However, the advancement of surgical treatments and modern chemotherapy drugs has improved
outcomes for spinal cancer patients while new radiotherapy options have provided alternative
treatment methods. As only up to 10% of patients with symptomatic spine metastases can be
treated with surgery, radiotherapy is especially important in providing pain relief and the prevention
or reversal of neurological dysfunction [22,23,47].
Figure 2.16: The para-spinal area neighbouring the spine. Modified from Vanderbilt [11].
Spinal Stereotactic Ablative Body Radiotherapy
SABR has emerged as an innovative option for treatment of spinal metastases [22]. Heterogeneous
dose distributions are achieved in SABR by utilising steep dose gradients (see section 2.1.2) and
small fields so the treatment site receives an ultra high, ablative dose and the planning risk volume
(defined in section 2.2.2) receives minimal dose. Ultra-high dose per fraction (approximately 6 Gy -
24 Gy) used in SABR may raise the level of palliative treatment for spinal metastases by offering
long term alleviation of pain and consequently improving quality of life [22,24,47]. This is important
for patients with more indolent cancer or limited metastatic disease. A clinical trial conducted by
The Trans Tasman Radiation Oncology Group (TROG) for Cancer Research, SC24, has explored the
efficacy of spine SABR and established a technique for clinical implementation [36]. Now in phase
III, the trial is investigating the radiation dose-response for pain control by comparing SABR to
conventional radiotherapy treatments of approximately 1.8 - 2.2 Gy per fraction regimes. Following
the recommendations from phase II/III of SC24, ACH started spine SABR treatments in 2019,
delivering 24 Gy in 2 fractions. Under-delivery of this dose could mean the cancer cells are not
completely destroyed resulting in poor patient outcomes. In terms of radiation delivery to the
tumour, over treating would not result in any adverse effects. However the delivery of too much
radiation to the tumour will likely mean healthy tissues nearby will receive dose in excess to what is
necessary. In effect, the amount of dose that can be delivered safely to tumours such as spinal
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metastases is limited by dose constraints to neighbouring vital organs such as the spinal cord. Dose
constraints for the spinal cord adds complexity to treatments but has been strictly established to
reduce the potential of paralysis (also known as myelitis) [22].
A conservative approach to these treatments was taken to ensure the maximum point dose to the
spinal cord PRV (defined later in section 2.2.2) does not exceed the SC24 recommended limit of 17
Gy total dose. While the spine region does have the benefit of minimal breathing-related organ
movement, safely delivering a more intensive dose of radiation requires not only spatial precision due
to the proximity of the spinal cord but also accurate dose delivery of the treatment plan [22]. Hence,
not only is the precise knowledge of tumour location from pre-treatment imaging needed, but the
accurate alignment of the tumour location (i.e. the patient) prior to and during the treatment is also
required. The convention at ACH for planning SABR spine plans is to position the treatment
isocentre within the spinal cord. To ensure the treatment plan delivered on a linac treatment unit is
precise and accurate to what is planned in clinical software, planning procedures, standardised in
local protocols are utilised and are detailed below so the reader understands the planning process.
Important aspects of the treatment plan are also described to highlight what is considered when
assessing the quality of a treatment plan.
2.2.2 The Planning Process
The planning process is one of the most important aspects of a radiotherapy treatment as the
success of a treatment is dependent on the quality of a treatment plan. Hence, the planning process
is extensively assessed to ensure the treatment plan has been optimised for each patient and that the
treatment plan can accurately and safely be delivered to this patient. The processes involved in
determining a treatment plan are provided in the subsections below, as the reader should have an
overview of the treatment planning process to understand how the treatment planning system (TPS)
is utilised for this task. A description of the RayStation TPS at the focus of this thesis is given later
in the section 2.3.
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Pre-Treatment Imaging
The radiotherapy treatment process begins with pre-treatment imaging of the patient. The current
standard of care for radiotherapy in modern facilities is to acquire a three dimensional (3D) set of
images using a computed tomography (CT) scanner [39]. From the CT image, the tumour and
healthy tissue are identified in the initial steps of treatment planning, described below. The CT
measures and displays a pixel shade corresponding to the Hounsfield Units (HU) of materials







Where µ is the linear attenuation coefficient and µH20 is the linear coefficient for water. The HU is
converted to the mass density in RayStation using a CT HU to density table that is calibrated
during the commissioning of the CT by scanning materials of known mass density [7, 39]. A Siemens
SOMATOM Sensation CT scanner was used in this project to scan and acquire mass density
information of the anthropomorphic phantom used in this research, detailed in chapter 3.
During CT imaging for spine SABR treatments at ACH, tattoos and metal ball-bearings (BBs)
placed on the patient’s skin provide landmarks to identify the alignment of the patient with respect
to the CT scanner and therefore CT images. The tattoos aid patient setup on the treatment unit to
a similar position in which they were scanned.
Treatment Planning
Treatment planning begins with the transfer of pre-treatment, CT images into the treatment
planning system (TPS). After this transfer is complete, the radiation oncologist (RO) will contour
particular volumes called regions of interest (ROIs) from CT images in the TPS. It is important that
these CT images have adequate quality to enable the RO to contour these ROIs. Hence, additional
images (MRI or PET) may be fused with the CT image to improve soft tissue contrast. Sometimes,
artifacts are seen in images - for example, metal artefacts caused by the presence of high density
materials [49]. Metal artifacts will affect the displayed density of materials surrounding the metallic
material in CT images, so additional contouring may be required to over-ride the material’s density
to what is expected [49].
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One of the contours outlined by the RO is the ‘gross tumour volume’ (GTV) (figure 2.17). The GTV
may be expanded to a ROI called the ‘clinical target volume’ (CTV), which accounts for the
sub-clinical, microscopic disease which should be eliminated but can not be identified in images.
Furthermore, the ‘planning target volume’ (PTV) expands on the CTV to account for all the
possible geometric variations and inaccuracies, ROI contouring errors, patient positioning and
set-up, linac and TPS uncertainties. Organs at risk (OARs) of receiving high levels of radiation due
to their proximity to the treatment site are also identified. These are defined in ICRU 50 as “normal
tissues whose radiation sensitivity may significantly influence treatment planning and/or prescribed
dose”. To avoid serious complications, uncertainties and variations of the OAR during treatment
may be considered by expanding the OAR to the ‘planning risk volume’ (PRV). During planning,
doses to the PRVs are assessed to ensure they are below appropriate thresholds [50]. For spine
SABR treatments one of the major OARs is the spinal cord.
The aforementioned ROIs are formally defined in ICRU 50 and 83 which states “it is important to
define in a clear and concise way the volume(s) to be treated to the prescribed dose(s)” [12, 51].
Figure 2.17: Volumes of interest as defined in ICRU [12]. Gross Tumour Volume (GTV); Clinical
Target Volume (CTV); Internal Target Volume (ITV); Planning Target Volume (PTV); Organ
at Risk (OAR); Taken from Podgorsak [7].
Following the definition of ROIs (figure 2.18), the radiotherapy planner will create a treatment plan
in the TPS following the local standardised planning procedures for the particular treatment
technique and treatment site. For spine SABR treatment planning, inverse planning is used, which
begins with defining the treatment objectives - for example, a minimum dose of 25 Gy to the PTV
named “PTV24 eval” and maximum dose of 14.5 Gy to the PRV named the “SpinalCord PRV”
listed in figure 2.19. Following the definition of the beam arrangement and treatment objectives,
24 Chapter 2. Background
Figure 2.18: ROIs defined in a typical SABR spine treatment plan at ACH. The gross tumour
volume (GTV, in red) is considered tumour identifiable from the pre-treatment image.
treatment defining parameters such beam intensity are optimised by the TPS through minimisation
of dose-cost functions in simulated annealing. This is outside the scope of this thesis and is not
detailed here. Instead the reader can find a description of inverse planning and simulated annealing
in the text by Mayles [9].
Figure 2.19: An example of some objectives used to plan SABR spine treatments defined in
the ACH planning protocol for SABR spine treatments.
The dose calculated in the TPS used in this project, uses a collapsed cone convolution dose
calculation algorithm based on the mass densities mapped through the patient anatomy, captured in
images on the CT scans (described in further detail in section 2.2.2).
2.3 The Collapsed Cone Convolution Algorithm
As previously discussed, the purpose of a TPS is to calculate as accurately as possible and within a
reasonable amount of time, the distribution of dose within the patient. There are many TPSs
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available but for this work we are confined to the RayStation v8B TPS (RaySearch Laboratories,
Stockholm, Sweden) used at ACH for SABR spine treatments. The RayStation v8B TPS used in
this research utilises a collapsed cone convolution (CCC) algorithm to calculate dose, first introduced
by Ahnesjö in 1989 [52]. This method considers primary photon transport and secondary transport
of photons and electrons, created from the initial primary photon interaction event separately (see
photon interactions described earlier in section 2.1.1). This section gives an overview of the CCC
algorithm for dose computation with a particular focus on key aspects relevant to this research. This
is predominantly based on the RayStation v8B Reference Manual [5] however supplementary
explanations from Wieslander [53], Oelfke [14], Karlsson [13] were used. For greater detail and the
complete mathematical formalism of the CCC algorithm, the reader is directed towards the paper by
Ahnesjö [52]. This section begins with an overview of theory behind the CCC algorithm and then
describes how RayStation implements this to estimate dose delivered to the patient.
2.3.1 Theory of The Collapsed Cone Convolution Algorithm
The CCC algorithm derives the dose distribution from first principles, accounting for photon
interactions described in section 2.1.1 as well as geometrical and physical characteristics of the
particular patient treatment using modelled dose distributions. While the kerma (defined in section
2.1.1) considers only the kinetic energy transferred or released to a given mass, the total energy
released per unit mass (TERMA) considers the total energy released to a given mass. The TERMA
represents the transport of a primary photon defined for a point r, photons of energy E and an










Where µ(E,r) is the linear attenuation coefficient of the absorber at r and ΨE(r0) is the energy
fluence differential in energy on a reference plane.
The point spread kernel (PSK) represents the secondary transport of electrons and photons that give
the distribution of energy or dose to a point r, from a single photon interaction at point r’, in water.
The PSKs are often calculated from Monte Carlo simulations for a discrete energy. Poly-energetic
PSKs are derived from the weighted combination of mono-energetic PSKs according to the energy
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spectrum at a particular radiological depth, accounting for depth hardening and off-axis softening
effects. Considering poly-energetic PSKs in homogeneous media, the PSK function becomes spatially




TERMA(r′)ρ(r′)h(E, r − r′)dV dE, (2.8)
Where r’ is the point of the primary interaction, h is the PSK and ρ is the mass density.
Due to the computational demand of the convolution calculation (equation 2.8) it is very
time-consuming. To reduce computation times, Ahnesjö introduced the collapsed cone
approximation to increase dose calculation speed. In this approximation, the PSK is divided into a
number of cones, each emanating from the primary interaction point (the origin), where the energy
deposited within a cone is collapsed to the central ray or axis of that cone (figure 2.20). The cones
are unevenly distributed, with a larger number of cones in the forward direction due to the
forward-peaked nature of energy release from a primary photon interaction [2, 53]. This efficiently
simplifies and reduces the number of scatter directions from the kernel. At large distances from the
kernel origin, the end of the cone covers several voxels. The voxels intercepting the cone axis are
defined as containing all the deposited energy. The voxels not aligned on the cone axis are not
assigned any energy but are compensated by the energy from other collapsed cone lines. Hence,
further from the origin, the accuracy of the approximation decreases as there is an increased number
of voxels that do not align to the axis of the cone. However, the relative importance of this is reduced
by the rapid decrease of energy deposition with increasing distance from the origin (defined in the
PSK). The dose deposited in a calculation voxel is assigned to the mid-point or centre of the voxel.
2.3.2 The Collapsed Cone Convolution Algorithm in RayStation
This section described the implementation of the CCC algorithm in RayStation, to calculate dose
delivered to the patient. The CCC dose computation in RayStation is performed in three steps.
Initially, the energy fluence is calculated, next the TERMA is computed and the last step is the
convolution with the PSK. These steps are outlined in this sections below.
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Figure 2.20: a) Angular discretisation of a point kernel in the collapsed cone approximation
resulting in conical sections of the point kernel. Each conical sector ‘collapses’ onto a single
transport direction aligned to the cone’s axis (black arrows). b) The dose distribution can be
determined by following the fixed transport lines while collecting and depositing energy in each
intersected voxel. Taken from Karlsson [13]
Determination of Electron Density, Effective Density and Radiological Depth
To compute the radiological depth and attenuation of a voxel at radiation therapy energies the
photon attenuation needs to be recalculated. The mass density ρm can be related to the electron






1 + α(1+ < Z > material)
1 + α(1+ < Z > water)
, (2.9)
Where Z is the atomic number. As mentioned previously in section 2.7, the importance of pair
production increases with increased Z of the material irradiated. This effect is accounted for by






1 + α(1+ < Z > material) ln(E)E
1 + α(1+ < Z > water) ln(E)E
, (2.10)







Where < Z/A > is the weighted mean nuclear ratio (the number of protons Z, to number of protons
and neutrons A i.e. the atomic number), f i is the weight fraction of atom type i in the material and
α is 1.775 x 10 -3 [5]. The effective density is calculated for the entire dose grid and radiological
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Where r0 is the point where the ray crosses an arbitrary reference surface, Ei is the discrete energy
and r is the position.
Energy Fluence
The energy fluence is computed by consideration of two sources, the primary source and the
secondary source. The primary source models the target and the secondary source models the
flattening filter as depicted in figure 2.21. The two sources are projected through the collimators
onto the fluence plane. The resolution of the fluence grid is 1 mm x 1 mm for the primary source
and 3 mm x 3 mm for the secondary source. These sources are modeled with Gaussian intensity
profiles. The primary source has an intensity profile characterised by the target dimensions and is
elliptical whereas the secondary source has a circular Gaussian intensity profile. Given the
Figure 2.21: A diagram showing the computation of the energy fluence from two sources, the
primary source and the flattening filter source. The energy fluence grid at the isocenter plane,
perpendicular to beam direction is shown (left). The TERMA for a voxel is computed using
the fluence, tracing back to the surface and then down into the patient as if all rays originate
at the primary source (right). Taken from the RayStation v8B Reference Manual [5]
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radiological depth d(r) given by equation 2.12, the primary energy fluence Ψ can be defined as
Ψ(d(r), Ei) = Ψ0 e
-µ(Ei)d(r) (2.13)
Where Ψ0 is the energy fluence in the reference plane. Beam divergence is taken into account by
applying the inverse square law.
For FFF beams, the weight of the flattening filter source is reduced in the beam model and the beam
parameters are manipulated to adjust the beam profile to a typical FFF profile shape, as depicted in
figure 2.11 [54].
TERMA





Ψ(r, E) dE (2.14)
where d(r) is the radiological depth, Ei is the discrete energy, ρm is the mass density, µ is the linear
coefficient and Ψ is the energy fluence. The primary energy released in the first interaction expressed
in the TERMA most likely results from a Compton scattering event (figure 2.2) for high energy
photon radiotherapy of human tissue (i.e. soft tissue interactions, section 2.1.1).
The Point Spread Kernel
The primary energy released in the first interaction expressed in the TERMA most likely results
from a Compton scattering event (figure 2.2) for high energy photon radiotherapy of human tissue
(i.e. soft tissue interactions, section 2.1.1). Hence, the particles interacting in the initial Compton
scattering event are the primary photon and an electron in the material (section 2.1.1). Following
this, a cascade of interactions occur that inevitably result in the deposition of the primary photon’s
energy. In the final states of this cascade, particles in Compton scattering involve a free energetic
electron and a scattered low energy, secondary photon. The free electron releases energy locally,
within the first centimeter [7]. However a large proportion of the energy released from the secondary
photon may range several decimeters. The point spread kernel (PSK) describes the spatial
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distribution of energy resulting from the initial interaction of the primary photon, where there is a
photon energy fluence in the forward direction, θ=0°(figure 2.22). Mono-energetic PSKs in
RayStation have been pre-computed in water using EGSnrc, a Monte Carlo simulation package.
These are spatially invariant when applied to water and are cylindrically symmetric, stored on a two
dimensional polar grid with radius r and azimuth/polar angle θ as PSK(r,θ,E). In RayStation, the
CCC algorithm uses 128 trace directions emanating from the primary interaction point.
Figure 2.22: Point spread kernel (PSK) that describes the energy distribution in a 3D spherical
grid from a primary photon. The PSK in the spherical grid is defined by its radial distance
and azimuthal angle. Taken from the RayStation v8B Reference Manual [5].
As the linac beam output actually is comprised of a spectrum of photon energies, poly-energetic
PSKs should be used to describe the deposition of energy from a primary photon source. In
RayStation, the poly-energetic PSK is derived as a weighted sum of monoenergetic PSKs,
pre-computed in water. Hence, the CCC algorithm implementation in RayStation calculates the
absorbed dose-to-water.
Each voxel with significant TERMA creates a PSK. The PSK is calculated from the energy
spectrum corresponding to the radiological depth, off-axis softening and beam hardening of the
calculation point. The resulting density-scaled-PSK is extended from the primary photon interaction
point when a region with an electron density (ρ1) that is smaller than the density of the
homogeneous medium (ρ0) is encountered (figure 2.23). Conversely the kernel shrinks where energy
transported encounters a region with electron density ρ2, greater than ρ0.
The dose is calculated from the total accumulated dose through tracing out in different angular
directions. Moving out in a trace direction, the contribution from an intersected voxel is calculated
by integrating the kernel over the radiological intersection length and scaling it with the TERMA for
the intersected voxel (figure 2.24). This process is iterated for all the TERMA voxels intersected in
all trace directions.
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Figure 2.23: Isodose curves of density scaled kernels. The range of energy spread behind tissue
inhomogeneities is adapted to the radiological distance between the interaction point at r’ and
the dose point r. This leads to deformation of the isodose lines behind inhomogeneities as
shown on the right. Taken from the Oelfke [14]
Figure 2.24: The photon dose is computed as a two step process: the photon fluence Ψ, is in
the first used to calculate the TERMA, and in the second step the TERMA is combined with
the PSKs, to obtain dose. Taken from the RayStation v8B Reference Manual [5].
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Implementation for Heterogeneous Media in RayStation
In RayStation, the ρeffective, material/ρeffective, water is related to the ρm, material/ρm, water by summation
of equation 2.10 over a given beam energy spectrum, at isocenter in air for several selected materials.
These materials are air, lung, adipose, tissue, muscle, cartilage, bone, aluminium, iron, gold and
osmium materials [5]. The mass density of a material is converted to the effective density from these
relations. If the material is different to those listed above, linear interpolation between the mass
densities of these materials is used. The transformation from the mass density to the effective
density is applied to each voxel over the patient dose grid.
The linear attenuation of the material (other than water) is rescaled using the effective density by
µ(r, E) = µ0(E)ρeffective(r, E)/ρeffective H2O(E) (2.15)
Where µ0(E) is the energy dependent attenuation coefficient of water and
ρeffective(r, E)/ρeffective H2O(E) is the ratio of the effective density of the material to water, at point r
and energy, E. For media with an atomic number similar to water, the effective density is
approximately equal to water (figure 2.25). As evident from figure 2.25, the effective density is very
strongly correlated to the electron density, particularly for materials with similar density to water.
As described later, in section 2.4.1, the electron density is the most important density in
radiotherapy.
2.3.3 CCC Algorithm Approximation Weaknesses
The CCC algorithm is one of the most advanced model based algorithms commercially available [5].
This algorithm has been specifically designed for relevance in the clinical setting and accounts for
inhomogeneities by density scaling the polyenergetic kernel as discussed in section 2.3.2. Hence,
approximations used in this algorithm may lead to inaccuracy in computed dose, outside of clinically
relevant situations. The polyenergetic kernel used in the RayStation CCC algorithm has been
calculated in water, where in the MV photon energy range, Compton interactions provide the
dominant source of primary dose (section 2.1.1) [52]. However, as material densities diverge from
water density, the applicability of density scaling becomes less valid as the proportion of photon
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Figure 2.25: The conversion from mass density to electron and effective density for a 6 MV
beam. The effective density is used both in TERMA and point spread kernel computation.
Taken from the RayStation v8B Reference Manual [5]
interactions shift from a dominance of Compton scatter towards photoelectric or pair production
(figure 2.7). RayStation eludes to this by stating that clinics should test the “dose computation and
beam model for the full clinically interesting range of densities, inhomogeneities, field sizes, field
positions and SSDs.” Hence the ability or limitations of the TPS to accurately calculate dose
through materials of high densities, like metal, should be investigated prior to the delivery of
treatments at sites involving these materials [55]. In this thesis the dose is measured and compared
to the dose estimated in the TPS. An overview of the equipment used for dose measurements is
given in section 2.4.
2.4 Dose Measurements
To assess the accuracy of the TPS dose measurements are made to analyse the dose delivered on the
treatment machine. Dose measurements are also performed after the treatment planning process to
test the deliverabilty of the plan in a process called patient specific quality assurance (PSQA). This
process ensures the plan designed in the TPS matches what is delivered on the treatment unit.
Traditionally, dose measurements are performed with a suitable dosimeter to assess the dose at a
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point or the 2D planar dose distribution, within a phantom which is a device that acts as a surrogate
for the patient, described in section 2.4.1. A description of suitable dosimeters used to measure dose
in SABR spine treatment plans is given in subsection 2.4.2. While comparing point dose differences
is trivial, the comparison of planar dose distributions is more complex. Typically a gamma analysis
is used in radiotherapy for this which is described for the reader’s understanding in section 2.4.4.
2.4.1 Phantoms
To verify the treatment plan, a phantom is used as a surrogate for the patient. Using a phantom
enables dose measurements inside the “patient” that normally can not be performed in real patients.
To closely replicate the patient the phantom materials should be tissue equivalent in terms of
physical but more importantly, radiological properties. Physical properties include size, shape and
mass density. Mass density ρm, defined by equation 2.16, where dm is the mass of a substance
divided by its volume dV, may be used as a crude measurement of tissue equivalence but gives little





The radiological properties such as the mass attenuation coefficient, mass stopping power, mass
scattering power and electron density of a material, help to characterise how radiation (e.g. photons)
may interact and deposit energy in the material as it traverses through it. These are defined by





Where Z is the atomic number of the material, A is the atomic mass number of the material, NA is
Avagadro’s number, a constant. Materials that closely match physical and radiological properties of
tissues are ideal substitutes however, this is not always achievable. The electron density ρe (number
of electrons per unit mass), should be the main determinant in selection of phantom material for
photon beams [7]. The most universal substitute for soft tissue is liquid water although for practical
reasons solid (e.g. SNC Gammex Solid Water® HE [56]) and virtual water are often used.
An anthropomorphic phantom closely resembles human anatomy in shape, size and heterogeneity of
tissues compared to typically used simplistic phantoms such as a tank of water. There are a number
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of anthropomorphic phantoms commercially available (e.g. The Alderson Radiation Therapy
phantom in figure 2.26), each designed to facilitate measurements with different dosimeters described
in section 2.4.2. This project involved the design of a specialised anthropomorphic phantom for dose
measurements of spine SABR treatment plans with and without spinal metal implants.
Figure 2.26: An example of an anthropomorphic phantom, the Alderson Radiation Therapy
phantom that is composed of bone, soft tissue and lung equivalent materials moulded to the
shape of a human head and torso. Taken from Radiology Support Devices Inc. [15].
2.4.2 Dosimeters
As mentioned in the previous chapter, a phantom was designed and produced for use in this research.
One of the initial considerations in the concept of this was identifying suitable dosimeters required
for dose measurements. Small field dosimetry was considered as small fields are often utilised in
SABR treatments. Dosimetry of small fields requires a consideration of Bragg-Gray cavity theory.
The Bragg-Gray cavity theory provides a relation between the absorbed dose in a dosimeter and the
absorbed dose in the medium containing the dosimeter. To apply Bragg Gray theory, the cavity (i.e.
active volume of the dosimeter) must be small in relation to the range of charged particles incident
on it, so the cavity’s presence does not introduce perturbations to the fluence of charged particles in
the medium. This requires establishment of charged particle equilibrium (CPE) across the volume of
the cavity introduced to the medium. CPE exists if each charged particle leaving the volume is
replaced by a particle, of identical type and energy, entering the volume [2,9]. Bragg Gray cavity
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theory assumes that the absorbed dose in the cavity is deposited solely by charged particles crossing
it. For small fields, it is challenging to fulfill these conditions as the collimator opening blocks off
part of primary photon beam, reducing the amount of charged particles crossing or contributing to
absorbed dose in the cavity of the dosimeter. For absorbed dose-to-water measurements, a Bragg
Gray cavity is ideal but will depend on the size of the cavity relative to the range of electrons in the
cavity medium and the electron energy.
The size of the detector relative to the beam dimensions was also considered to minimise volume
averaging effects [21,57]. Volume averaging occurs when the precision of the dose measured by a
dosimeter, at a point, is blurred since the dose measured is the average of the dose collected over the
active volume of the dosimeter and not the dose measured at that point. In other words, volume
averaging effects reduce the resolution of point measurements. The resolution of the measurement
should be comparable to the dose calculation grid size used in the RayStation TPS to estimate dose.
Careful selection of dosimeters for SABR plan assessment in this research was vital for an accurate
comparison of measurement dose to the RayStation calculated dose that used a 3D 1 mm x 1 mm
dose calculation grid.
2.4.3 Dosimetry of SABR Spine Treatment Plans
SABR dosimetry techniques involve the assessment of steep dose gradients required to achieve
complex dose distributions. As previously mentioned in section 2.2.1, precision and accuracy of
treatment plan delivery is pivotal for the success of this treatment technique. As SABR relies on
MLCs to modulate the intensity of dose delivered dosimeters that measure the integrated dose
response (vs. instantaneous) are necessary to assess the accumulated dose delivered. Ionisation
chambers, film, diamond detectors, thermoluminescent dosimeters, diodes and gel dosimeter are
different types of dosimeters that offer high spatial resolution, customisable volumes, ease of use or
excellent 3D resolution. While these dosimeters were considered for use in this study, only ion
chambers and film were selected due to their energy independence, angular independence, ease of
use, dosimetric resolution and inevitably accessibility for use in this thesis. More information on
these two types of dosimeter are given in the following subsections.
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Ionisation Chambers
An ionisation chamber (IC) is generally the preferred choice for absolute point dose measurements as
they exhibit dose linearity, stability, beam energy independence and angular independence. ICs
should be used to verify the dose output from the linac (measured in cGy per monitor units) and
critical structure doses (e.g. dose to the spinal cord). ICs are available in different sizes, with active
volumes ranging from 0.01 - 30 cm3.
Figure 2.27: The 0.04cc IBA ionisation chamber used in this research. Taken from IBA Detector
Brochure [16].
An IC is essentially an air-filled cavity containing a central collecting electrode, surrounded by a
conductive outer wall (figure 2.28). Irradiation of the chamber ionises air particles in the chamber
cavity. When a potential difference is applied across the outer and central electrodes, the ions can be
collected and measured as current via connection of the IC to an electrometer. An insulator is used
to separate the wall and collecting electrode to reduce any leakage of current. Open air ICs require a
temperature and pressure correction for changes to the mass of air within chamber volume with
ambient temperature and pressure changes as defined in International Atomic Energy Agency
(IAEA) Technical Report Series (TRS) 398 by equation 2.18 [7].
Figure 2.28: Basic design of an ionisation chamber. Taken from Podgorsak [7]
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As stated in IAEA TRS 398 dosimetry protocol used throughout Australasia, a small-volume IC
should be cross-calibrated against an IC traceable to a primary standards dosimetry laboratory
(PSDL) for absolute dose measurements using a cobalt beam [58]. The IC traceable to a PDSL at
ACH is the departmental reference IC, that has an absolute dose-to-water calibration factor
(ND,W,Qo) from its calibration at the PDSL, The Institute of Environmental Science and Research
(ESR).
IAEA TRS 398 defines absolute dose-to-water, Dw from measurements M1 (at the normal operating
voltage, V1) via equation 2.19. In this equation, kQ,Q0 is the beam quality correction factor that
accounts for the difference in dosimeter response to Cobalt-60 and 6 MV beam energy. The ks is the
saturation correction factor that corrects for the lack of complete charge collection (due to ion
recombination) of an IC (equation 2.20). The polarisation correction factor, kpol corrects for change
in IC response with a change of polarity of the polarising voltage applied across the outer and
central electrodes (equation 2.21). The kelec is the correction factor applied to correct for using an
electrometer different to the electrometer used to calibrate the ionisation chamber. Additionally, the
pressure and temperature correction factor, kTP accounts for a difference in temperature and
pressure specified by the PSDL and the temperature and pressure of the environment at the user
facility where the chamber is used (equation 2.18).
kTP =
(273.2 + T )




Where T and P corresponds to the environmental temperature and pressure respectively (taken at
the time of measurement). The T0 and P0 corresponds to the reference temperature and pressure
which are 20°C and 101.3 kPa respectively [59].
Dw(Gy) = MND,w,Q0kQ,Q0 = (M1kTPkeleckpolks)ND,w,Q0kQ,Q0 (2.19)











Where M2 is the measurement corresponding to a lower polarising voltage (V2) than the normal
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Where M- is the measurement corresponding to the reversed (negative) normal operating voltage
and M+ is the measurement corresponding to the normal operating voltage (M+ = M1).
SABR treatment plans utilise a combination of low and high dose rates to create a conformal dose
distribution. This treatment uses a 6 FFF beam capable of dose rates an order of magnitude higher
than a flattened beam as there is no attenuation of photons by the flattening filter (figure 2.8). For
example, 600 MU min-1 is a typical dose rate used for conventional treatments with a 6 MV beam
and 1300 MU min-1 is typical for SABR spine treatments with a 6 FFF MV beam. Higher dose rates
may affect the response of the dosimeter and electrometer system used for absolute dose
measurements. This can be quantified by determination of ks for the specific dose rate (equation
2.19, section 2.4.3). While typical ks values are close to 1.0, for lower dose rates we expect ks to fall
just below 1.0, while we expect it to increase to just above 1.0 for higher dose rates.
Film
Film offers a method to assess a 2D planar dose distribution and absolute dose at high spatial
resolution down to 25 µm but requires careful handling, time consuming pre-calibration and readout
processes for absolute dose measurements. Film is an appropriate choice for spatial measurement of
conformal treatments like SABR as it offers high resolution, required to assess steep dose
gradients [60]. Additionally, film has weak energy dependence from the kV to MV range. Modern
radiochromic film such as GAFchromic EBT3 film (Ashland, Bridgewater, USA) is self-developing,
which reduces the film processing time required for dosimetry. A box of GAFchromic EBT3 film (25
sheets) and an EPSON scanner for densitometry was available for use in this research. Absolute
dosimetry with EBT3 film involves scanning irradiated pieces of film with varying dose into a
computer, described later in section 3.1.3. Each piece of film is used to construct a calibration curve
(figure 2.29) of film optical density (or scanner response) versus exposure (absolute dose used to
irradiate each piece of film), usually on a logarithmic scale.
Ultimately for spine SABR treatments, the dose in the fall-off area from PTV to Spinal Cord PRV is
the most clinically relevant parameter [61]. Hence, dosimeters that measure the dose distribution
with high resolution like film are required for the assessment of these types of treatment plans [61].
To compare the planar dose distributions measured with film to that calculated in RayStation, a
gamma analysis is commonly used in radiotherapy, described in the next section.
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Figure 2.29: High and low dose response film calibration curves created for absolute dose
measurements with GAFchromic EBT3 film used in this study (batch number 04022001).
2.4.4 Gamma Analysis
The gamma analysis, introduced by Low et al. [62] is a quantitative test to compare the agreement
between two dose distributions. The gamma analysis was developed to identify regions that matched
in dosimetric and spatial terms by utilising both dose difference and distance to agreement
assessments explained further below. This analysis is typically utilised to compare film
measurements to the dose estimated in the treatment plan to identify the level of agreement between
these dose distributions.
Dose Difference and Distance to Agreement
Dose difference is defined as the percentage difference between the same spatial point in each dose
distribution. In regions of low dose gradients the dose difference is an effective tool to assess the
agreement between two dose distributions. However regions of steep dose gradients are
hypersensitive to misalignment of the distributions introduced by uncertainty or error in
measurement set-up. In these regions, large dose differences may be attributed to errors in
measurement alignment, hence the concept of distance to agreement (DTA) is more relevant than
the dose difference. The DTA is applied for each reference point by digitising the evaluated dose
distribution for the closest point with the same dose value as the reference point. The distance to
this closest point (within a tolerance defined by the user) is the DTA.
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The Gamma Value
The gamma analysis combines the dose difference and DTA measures into one tool. This analysis
method is beneficial as the dose difference has greater significance in regions of low dose gradients
and the DTA has greater significance in regions of high dose gradients (figure 2.30). The gamma
Figure 2.30: A one-dimensional representation of the gamma analysis in (a) low and (b) steep
dose gradients. For low gradients the distance to agreement (DTA) becomes negligible in the
gamma analysis. For steep dose gradients, the dose difference becomes negligible. Taken from
Miften [17].
analysis results in the calculation of a value known as the gamma value which indicates the
percentage of dose points that show agreement between the two dose distributions within the gamma
acceptance criterion set by the user. A complete description with mathematical derivations for this
formalism can be found in the work described by Low et al. [63]. Clinically, both a 2%/2mm (dose
difference tolerance = ±2%, DTA tolerance = ±2 mm) and 3%/1mm (dose difference tolerance =
±3%, DTA tolerance = ±1 mm) gamma criteria are used for PSQA gamma analysis of film
measurements of SABR spine treatments at ACH (figure 2.31). A gamma value of <90% indicates
disagreement between the dose distribution measured with film and dose calculated in the treatment
plan (i.e. failure of the pass tolerance level) which prompts further investigation in the
appropriateness or deliverability of dose estimated in the treatment plan. An example of gamma
analysis conducted using Sun Nuclear Corporation (SNC) Patient Software (SunNuclear Corp.,
Melbourne, Florida) seen in figure 2.33 using the 3%/1mm gamma criteria shows measured dose is
slightly colder than calculated dose at the center and edge of the dose distribution. For this plan, the
gamma value, or number of points meeting the gamma criteria of 3%/1mm was 95.6%.
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Figure 2.31: An example of absolute gamma pass rates for gamma analysis of film measurements
performed during PSQA of SABR spine treatments at ACH.
Figure 2.32: Example of gamma analysis in one dimension: ‘Set 1’ refers to measured point
doses and ‘Set 2’ is the calculated reference dose distribution for comparison.
The gamma analysis is compared to the patient fluence recalculated in the TPS on a virtual model
of the phantom, where the measurement devices are placed. This is an important final step in the
development of radiotherapy treatments to ensure they are safely delivered to patients. An example
of a gamma analysis (described in section 2.4.4) to compare the measured dose distribution to that
calculated in the TPS is shown in figure 2.33. Validation of the plan through the measurement of
absolute dose and a quantitative registration of the spatial locations of this dose are used for this
assessment. The registration process should allow a link between the dose measurement location
using the co-ordinate system of the treatment linac, to the co-ordinate system in treatment plans
created in the TPS. This can be a fixed measurement location within the phantom, aligned to the
linac isocentre identified with the positioning lasers on treatment units [62]. This research involved
the use of gamma analysis, to compare film measured dose distributions to the calculated dose
exported from the TPS as a 3D DICOM dose cube. The DICOM dose cube contains the distribution
of dose as calculated from the TPS following the application of the relevant treatment beam(s) to
the virtual models of the patient or phantom irradiated. The 2D plane in the DICOM dose cube,
corresponding to the plane where film was placed/measured at specific locations within the
phantom, were selected in the software used for gamma analysis, SNC Patient.
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Figure 2.33: An example of a dose distribution comparison between measurements with film
(left) and exported from RayStation (right) using analysis functions in SNC Patient software.
The point dose percentage deviation and gamma analysis were used to compare dose measurements
with the IC and film to the dose estimated in RayStation in this thesis. These comparisons, made
for measurements with and without metal in the phantom were examined to determine if the
accuracy of radiation estimated in RayStation to the radiation delivered to the phantom with metal
was equivalent to the accuracy without metal. A statistical approach was taken to assess the
equivalence between the datasets (comparisons with and without metal). The statistical methods
used in this thesis are described in section 2.5 so the reader understands their use in this work.
2.5 Statistical Methods
There are lots of statistical methods available to analyse research data but the two datasets created
in this research (one for measurement made with metal and the other, without metal) were
compared with consideration of small sample sizes, similar to clinical studies of this nature [64,65].
Statistical analysis is used to make probability based decisions on differences measured between
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study groups [65]. It should provide a realistic assessment on the reality and extent of conclusions
drawn from the analysis. For medical physicists, the improvement or validation of dose calculation
accuracy is required to refine practices; allowing dose to tumours to increase and dose to OARs to
reduce. Hence, statistical analysis is a useful tool for medical physicists to integrate into everyday
practice. Although statistically not ideal, this can be performed on small patient data sets reducing
pressure on resources (e.g. staff and accessibility to equipment) scarce in many clinical hospitals by
utilising bootstrap methods [65]. The method of statistical analysis utilised should be specifically
designed to answer the research question for a study. For this research, the aim is to prove
equivalence in any discrepancy between measured dose and RayStation CCC dose calculated in a
phantom with and without metal implants. This is to guide the decision to approve the clinical use
of the RayStation CCC dose calculation for spine SABR patients that have some metal-ware in
proximity to the treatment site. The next subsection gives a background on assessing datasets and
testing for equivalence while the following subsection provides an overview of the bootstrap methods.
The reader is directed to the text by Young [66], Hall [67] or from Efron [68] for a more
comprehensive technical explanation on the theories behind these statistical methods.
2.5.1 The Levene’s Test
The levene’s test is used to assess the equality of variances for a variable of two (or more) groups.
The null hypothesis tested assumes homogeneity of variance i.e. that the variance of each group is
equal. Typically, a significance level of 0.05 is used to compare with the p-value of the levene’s test.
If the p-value is less than 0.05, the obtained difference in the sample variances are unlikely due to
random sampling of a population with equal variances. Hence, the null hypothesis of equal variances
is rejected for a p-value less than 0.05 and we can conclude that the groups have unequal variance.
Conversely, from a levene’s test that returns a p-value above 0.05, there is no statistically significant
evidence against the null hypothesis, hence equal variance of the groups can be assumed.
2.5.2 Correlation Testing
The “Pearson” correlation test is widely used to test for correlation between datasets. That is, to
determine if a relationship between data-sets exists. The closeness of the relationship between
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datasets are expressed as the Pearson correlation coefficient (R value) that ranges from -1 to +1. A
-1 correlation coefficient represents a perfect negative correlation while a +1 correlation coefficient
represents a perfect positive correlation. If plotted against each other with a trend-line added, all
data points would fall on this linear trend line, showing a perfect correlation (figure 2.34). Data that
show no correlation will correspond to a correlation coefficient of 0, and points would be scattered on
both sides of this trend-line [69]. A p-value, calculated alongside the R value, based on the size of
Figure 2.34: The correlation coefficient corresponding to data plotted on a scatter plot. The
left and right plots show a perfect negative and perfect positive correlation, respectively. The
middle plot show data that show no relationship, where the correlation coefficient determined
equals zero. Taken from [18].
the data tested corresponds to the statistical significance of the correlation deduced from the
Pearson correlation test. Typically correlation coefficients corresponding to a p value under 0.05 are
considered statistically significant [18,69].
2.5.3 Equivalence Testing
The most common research question medical physicists are posed with, when commissioning a novel
treatment technique, is whether the new modality offers a statistically significant improvement from
the original technique. This research investigates if SABR treatments of spines with metal in close
vicinity is statistically equivalent to SABR treatments of spines without metal in close vicinity. In
this case, a two one sided t-test (TOST) is favoured over the traditional paired t-test as it overcomes
a number of limitations of the traditional paired t-test [64]. A TOST can be used to test for
equivalence between two datasets. The TOST tests the null hypothesis H0, that the datasets are not
equivalent. That is, the average difference between data sets (µδ) is above or below an equivalence
margin (equation 2.22).
H0 : µδ < lwr OR µδ > upr (2.22)
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HA : lwr < µδ < upr (2.23)
Where lwr is the lower limit of the equivalence margin, upr is the upper limit of the equivalence
margin and HA is the alternative hypothesis that the average difference between data sets is within
the limits of the equivalence margin i.e. data sets are equivalent.
Traditional paired difference tests are comparative studies that utilise a null hypothesis of
equivalence between datasets while equivalence studies do the opposite, by forming a null hypothesis
that there is a difference between datasets. In equivalence testing, the burden of proof shifts by
aiming to reject the null hypothesis of a difference (beyond a specified level) to conclude if the
datasets are equivalent [64]. If the evidence in favour of equivalence is not strong enough (i.e. HA in
the TOST test), non-equivalence can not be ruled out and the analyser can not conclude that the
datasets are equivalent. For equivalence testing, an acceptance criterion or equivalence margin
defines a range of values where the differences are “close enough” to be considered equivalent (e.g.
±5% difference in coverage in figure 2.35) [19]. Rationale in setting the equivalence margin is pivotal
and the researcher should set this prior to analysis to avoid type-II errors [64,70]. An example of a
type II error in this context is concluding from a non-significant finding that there is no effect when
there is in fact a real effect .
Figure 2.35: Results of traditional two-sided (left) and two one-sided test (TOST) (right)
procedures [19].
The Confidence Interval
A confidence interval (CI) is a type of estimate computed from the sample of data observed. It is a
range of plausible values for a statistical parameter of interest. The CI has an associated confidence
level that is the probability that the true parameter is contained in the proposed range. Compared
to the typically used p-value which simply provides a cut-off used to determine if the findings are
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‘statistically significant’, the CI provides a range of possible effect sizes [71]. Hence, the CI may be
preferable to the p-value as it aids in the overall interpretation of data [71]. A CI of 100(1− 2α)% is
used in the TOST to determine the difference in the two mean values and compare this to the
equivalence margin (lwr and upr) [64,72]. The α level of the equivalence test differs from the
confidence level of the interval and is defined as double the type-I error of α=0.05 because the null
hypothesis H0 is rejected only if both test decisions are accepted (equation 2.22) [64]. Hence, if we
are interested in an α=5% test of equivalence (i.e. 95% equivalence testing) we calculate the 90% CI
for the difference in means. When the lower limit of the CI is larger than lwr and the upper limit of
the CI is lower than upr we assume equivalence and reject the null hypothesis H0 for the alternative
hypothesis HA (equation 2.23).
2.5.4 Bootstrapping
Bootstrapping is a statistical methodology used to estimate an unknown statistic of interest known
as the sample statistic (e.g. the average). It is particularly useful for smaller sample sizes in which
the distribution of data is not evident [66,73]. It is used in a wide range of situations such as
estimation of population variance or the construction of CIs. Since its introduction by Efron in the
late 1990s, this has been the method of choice for statistical estimation as it offers highly accurate
inferences in many settings [66]. Bootstrapping methodology was developed based on a multitude of
ideas largely based on the frequentist desire for accurate repeated sampling properties. The
bootstrap is performed by re-sampling from the original sample of the population, with replacement.
The result of this is a B number of “resamples” of the same size as the original sample size, N, which
is used to evaluate the sample statistic [74]. This is reasonable as the bootstrapping concept is based
on the idea that the population can be thought of as a scaled up version of the sample [67,68,73]. If
the original sample is randomly selected from the population, this sample should look quite like the
actual population even though the actual structure of the population is almost always
unknown [73,75,76].
From the B bootstrapped resamples of size N, the distribution of the statistical parameter of interest
determined (e.g. the average of each of the bootstrap resamples) is typically visualised on a
histogram like in figure 2.36. From this distribution, the bias and standard error of the bootstrap
resamples can be determined. The bootstrap bias is the difference between statistic for the original
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sample and the average bootstrap statistic (calculated for each bootstrap resample). The standard
error is the standard deviation of the bootstrap resamples which gives an idea of the spread of the
bootstrap statistic about the mean bootstrap statistic. The CI can be determined from the
Figure 2.36: Histogram of average birth year determined from bootstrapped resamples of the
population. The 95% CI, representing the middle 95% of values was determined by the per-
centile method is indicated by the vertical lines. Taken from [20].
bootstrapped resamples using the percentile method [67,68,75,76]. For the TOST, as we are
interested in the 100(1− 2α)%=90% confidence level, the percentile method will determine the
middle 90% of values of the bootstrap distribution. This can be compared to the equivalence margin
to test for equivalence between data sets as in equations 2.22 & 2.23.
2.6 Conclusion
The sections above serve as background information relevant to carrying out the work presented in
the remainder of this thesis. It is given for the readers benefit and to assist as a reference in the
work presented and discussions that follow. Chapter 3 describes the process of designing and
creating an anthropomorphic phantom, which was the first step in this research work.
Chapter 3
Phantom - Design and Validation
In order to determine the dose delivered in SABR spine treatment with and without metal an
anthropomorphic phantom that can be used for dose measurements was designed and manufactured
at ACH. The purpose of this chapter is to present the design process for this phantom, including
methods used to validate it. A key step in this process was performing ionisation chamber and film
measurements to select suitable density over-ride values in the TPS for materials used to create the
phantom. The appropriate material density over-rides, described in section 3.2.2 were required to
estimate dose delivered from a treatment beam to a virtual model of the phantom created in
RayStation. These results are discussed in greater detail in section 5.1.
3.1 Methods
The design process for the anthropomorphic phantom named “MattL” began with resourcing and
selecting materials available for use followed by the conceptual layout of these materials and overall
functional design of the phantom. This was done via liaison with clinical engineering at ACH who
aided in the manufacture of the phantom.
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3.1.1 Materials and Resources
A suitable design for the anthropomorphic phantom will incorporate materials to mimic spinal
implants in the spine. This may include a section of material with similar density to soft tissue and
spinal bone but will need to utilise metal, ideally similar shape and size as those used in fixation of
the spine. The anthropomorphic phantom will also need to enable dose measurements with a
suitable dosimeter for assessment of spine SABR treatment plans.
Soft Tissue Equivalent Material
One of the important design considerations is the use of tissue equivalent material in lieu of human
tissue. Possibilities included liquid water and perspex however for this project it was decided to
make use of the external component of a phantom currently used for patient QA of spine SABR
treatment plans at ACH, “PhilM” (figure 3.1). PhilM is a homogeneous phantom designed to
geometrically mimic a simplified section of the human torso. During commissioning of PhilM the
mass density of the perspex material it is made of was verified as 1.105 g cm-3 which means the
electron density (that is very similar to the mass density) is approximately equivalent to soft tissue
(ρe= 1.0 g cm
-1) [77]. This phantom can be locked on the treatment couch top via a metal bar and
has external engravings used to identify the phantom’s geometric centre which is analogous to
tattoos placed on the patient during pre-treatment imaging (subsection 2.2.2).
Figure 3.1: A homogeneous anthropomorphic phantom, PhilM with removable cube insert
currently used clinically at ACH for spine SABR patient QA dose measurements.
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Vertebral Bone Material
Materials with similar density to spinal bone in figure 3.2 available for use in this research were
identified. These materials were CT scanned and imported into RayStation to identify the material
with density that best matches adult bone density. The mass density of adult bone, ρadult bone is 1.6
g cm-3 [78]. The lumbar vertebral section from CT images of a spine SABR patient were measured
and results agreed with the value from the literature (figure 3.3 & table 3.1). The value measured in
RayStation that best matches the value from the literature, from table 3.2 was PVC. Based on the
dimensions of three randomly selected spine SABR patients who have completed treatment from
ACH, a 5 cm diameter cylindrical PVC section was used to mimic a simplified section of the lumbar
spine.
Figure 3.2: Materials with similar density to bone available for incorporation in MattL phantom
used in this research.
Vertebrae Structure RayStation Displayed Density (g cm-3)
Body 1.20− 1.60
Pedicle 1.20− 1.60
V ertebral Arch 1.60− 1.90
Spinal Process 1.50− 1.80
Table 3.1: CT density of lumbar vertebrae structures measured in RayStation on imported CT
images from spine SABR patients.
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Figure 3.3: Vertebrae structures measured from the lumbar vertebrae section of CT images
from spine SABR patients.
Material RayStation Displayed Density (g cm-3)
Nylon 0.90− 0.95





Table 3.2: Material density measured in RayStation from imported CT images of materials.
7
Metal Implants
Four surgical grade “SpineArt” titanium alloy screws (ZTi = 22) designed for posterior fixation, four
titanium alloy set screws and a section of cobalt-chromium alloy posterior spinal fusion rods (ZCr =
24 and ZCo = 27) were donated from a local supplier of spinal implants, Pioneer Medical (figure 3.4).
The metal implants were incorporated into the anthropomorphic phantom and positioned to mimic a
posterior fixation on the spinal column (represented in figure 1.1).
Dosimeters
The phantom was designed to house two different dosimeters in a fixed position to measure dose
delivered. A small volume, 0.04cc Scanditronix/Wellhofer CC04 IC (IBA Dosimetry,
Schwarzenbruck, Germany) with stem diameter 10 mm (figure 2.27) was selected to minimise volume
averaging effects when measuring small fields used in SABR treatments. This was used alongside a
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Figure 3.4: Spine implants donated from Pioneer Medical incorporated into MattL phantom
used in this research.
UNIDOS E Electrometer (PTW, Freiburg, Germany) (figure 2.27). While a smaller 0.01cc IC was
available, this was not chosen for use due to significant leakage associated with a reduced sensitivity
of micro-chambers and over-response to low energy scatter, dominant at smaller field sizes
documented in literature [21,79].
The 0.04cc IC was cross-calibrated against an IC traceable to ESR for absolute dose measurements
in a 6FFF beam energy following TRS 398 recommendations. The calibration certificate from ESR
for the reference 0.6cc IC used for cross calibration ND,W,Qo , was 52.9 mGy nC
-1 ± 1% (coverage
factor 2, corresponding to 95% confidence). The IC reference point for these measurements was
taken on the chamber axis, at the centre of the chamber’s active volume.
GAFchromic EBT3 film (Ashland, Bridgewater, USA) was also selected to incorporate into the
design of the anthropomorphic phantom for high resolution 2D planar absolute dose measurements.
The GAFchromic film in this project came from the same batch and calibrated via pre-irradiation of
film pieces following established protocols at ACH (described in section 3.1.3).
3.1.2 Design
The MattL phantom is comprised of an external perspex shell and removable blocks (figure 3.5).
Perspex blocks of different dimensions border the central heterogeneous block, forming a cube
(removable block in figure 3.5). These blocks are rigid, which enables reproducible positioning of
dosimeters and parallel alignment of film to the sagittal or coronal planes. The heterogeneous central
block can be interchanged for other central blocks that do not contain metal implants (figure 3.6).
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Figure 3.5: MattL phantom: External perspex shell of PhilM with central removable blocks in-
serted. The central removable block can be interchanged with other central blocks, as described
later in section 3.1.2.
Figure 3.6: Disassembled components of MattL phantom used in this study.
The modular design of the removable blocks allows the rotation of the central block and more
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importantly the metal implants. When rotating the central block to different positions, this also
changes the arrangement of the IC or film to different locations in MattL (figure 3.8 & 3.9). When
the central cube insert is rotated, the surrounding perspex blocks are orientated appropriately to
align the central IC hole to the geometric centre of the MattL phantom. This can be checked on the
treatment unit using the external lasers that are aligned to the linac isocentre (figure 3.7). The
Figure 3.7: MattL with inserted sections of central cube structured to align the central ionisation
chamber to phantom’s geometric centre and treatment unit’s isocentre using the laser system.
versatility of the phantom enables orientation of metal implants to replicate not only a posteriorly
fixated implant (figure 1.1) but anterior or lateral fixations as well. Perspex IC hole plugs were used
to fill the insert holes when the IC was not inserted (figure 3.6 & 3.9). Similarly, dummy film pieces
were used when film measurements were not taken to minimise any air gaps between blocks (figure
3.9).
Interchangeable Central Block
There are three versions of the interchangeable central block (figure 3.6 & 3.9). These are comprised
of:
1. Metal implants, PVC and liquid water enclosed in perspex (MattLTi)
2. PVC enclosed in perspex (MattLPVC)
3. Perspex only (MattLperspex)
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Figure 3.8: Modular design of central cube insert used for measurements in this study. Blocks
can be orientated to rotate the metal ware towards a particular location or allow film or dose
measurements in a particular location.
Figure 3.9: Left: Interchangeable central block with metal implants orientated posteriorly (one
perspex block has been shifted for view of the metal implants and dummy film). IC plugs
inserted into holes and dummy film piece inserted. Right: Interchangeable PVC & perspex and
perspex only central block of MattL.
These blocks are geometrically the same shape and size including the location of the PVC and IC
insert holes. In this research the metal implants were orientated in the posterior position in the
anthropomorphic phantom as depicted in figure 3.10 and is referred to in the following sections of
this thesis as “MattLTi”. In this orientation, film was placed in the posterior and lateral film
positions (figure 3.9). Correspondingly, IC measurements in this orientation were made in the
central, anterior and lateral IC insert holes of the central block. Additional measurements made in
other versions of the anthropomorphic phantom were made for phantom validation purposes. Where
the anthropomorphic phantom with the PVC embedded in perspex central block is used, this is
referred to as “MattLPVC”. Where the anthropomorphic phantom with the perspex only central
block is used, this is referred to as “MattLperspex”. Collectively MattLTi, MattLPVC and
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MattLperspex are referred to as “MattL”.
While MattLPVC is used for validation of MattL and for SABR spine plan measurements in this
research (chapter 4), MattLperspex was produced solely for the validation of MattL (section 3.1.4).
The central heterogeneous block of MattLTi, that contains metal implants, PVC and liquid water
enclosed in perspex is essentially a water box holding a cylindrical section of PVC and metal
implants inserted into the PVC section (figure 3.10 & 3.11).
The design specifications of the central ‘water-box’ block created an engineering challenge to produce
a structurally robust section. The central location of the IC, designed to perform a point dose
measurement for the spinal canal (within the PVC vertebral bone surrogate) did not create a major
challenge. However, the lateral and anterior (or posterior) IC locations were designed to be as close
as possible to the PVC and metal implants for measurements close to these heterogeneous materials.
Similarly, the central block of the phantom was designed so the location of film measurements was
also as close as structurally possible to the heterogeneous materials. The final design produced had
two perspex walls with thickness of 5 mm, where film would be placed while the other two walls,
where the 0.4 cc IC or perspex IC hole plugs (largest diameter 10 mm) would be placed, were 15 mm
(figure 3.12). This central block did not show any signs of wall distortion or water leakage since it
was produced.
Figure 3.10: Structural layout of materials and location for placement of dosimeters in the
central insert used for measurements in this study. Film can be inserted in two orientations.
A 0.04 cc IC can be inserted in three positions. Spinal implants were embedded in the PVC
section of the central block (right).
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Figure 3.11: Central heterogeneous block: perspex box encasing metal and PVC surrounded
by liquid water.
Figure 3.12: Diagram of central heterogeneous block. Two thin walls of 5 mm thickness and two
thicker walls of 15 mm make up the what is essentially a perspex box encasing metal implanted
into a PVC cylinder of 50 mm diameter and liquid water.
Reference markings on the removable perspex blocks (surrounding the interchangeable central block)
were made to identify the film position for analysis (figure 3.13). This process is explained in “Film
Absolute Dose Measurements” in the next subsections.
Figure 3.13: Reference markings made on removable perspex blocks (surrounding the inter-
changeable central block) to identify the film position to aid processing film measurements.
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3.1.3 Dose Measurements
MattL was designed for independent point dose measurements with either a 0.04 cc Iba IC or film.
Absolute dosimetry with GAFchromic EBT3 film involves calibration and is well established in
protocols used clinically at ACH, described later in this subsection. However, the 0.04 cc IC
available for use in this project was not calibrated for absolute dose measurements. Hence, this
project involved cross-calibration of the 0.04 cc Iba IC for absolute dose measurements following
International Atomic Energy Agency Technical Report Series (IAEA TRS) 398
recommendations [58].
Ionisation Chamber Cross Calibration
The 0.04 cc Iba IC was cross calibrated with ACH’s reference IC for absolute dose measurements
using a Cobalt 60 beam following specifications detailed in IAEA TRS 398 [58]. These were made
according to IAEA TRS 398 using solid water in a 10 x 10 cm2 field size at 100 cm SSD, 5 g cm-2
depth, where tabulated values of a0, a1 and a2 can be found in table VII [58]. Additionally
measurements across a range of dose rates for the 6 MV FFF and 6 MV flat beams were made to
investigate the effect of dose rate on the ks value, required to determine absolute dose with the 0.04
cc Iba IC. Similarly, a kpol correction factor that corrects for the IC response to a change in polarity
were also determined for use in absolute dose measurements (equation 2.21) [58].
Placement of the Ionisation Chamber
When taking 0.04 cc IC point dose measurements, the user inserts the IC into one of the IC insert
holes and uses the IC hole plugs made of perspex to fill the IC insert holes not utilised. Additionally
dummy film is placed in the appropriate location to reduce any air gaps in MattL that may influence
the dose fluence measured (figure 3.9). MattL’s rigid block design improves the reproducibilty of film
placement (and the IC) however it does not allow shifts of the IC to other points of interests e.g. to
regions of homogeneous dose fluence. While translation of the IC within the phantom would be ideal
for highly modulated plans like spine SABR, it was important the positional accuracy of
measurements were robust and reproducible [62]. It was necessary to position the treatment
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isocentre to the geometric centre of MattL to enable a measurement of the spinal cord dose with
influence of the metal closely surrounding this point in the phantom.
For IC point dose measurements made in steep dose gradients present in spine SABR plans, small
setup inaccuracies can result in large differences of measured dose. IC measurements made in
homogeneous (and non-homogeneous) dose regions were identified by assessing the dose distribution
at each of the IC locations on the virtual model of MattL in RayStation. IC locations in a
homogeneous dose region were defined as a point at least 3 mm from the 98% or 102% isodose lines,
where the 100% isodose was set to the dose calculated at that point (figure 3.14). The placement in
a homogeneous dose region was considered when reviewing uncertainties in validation results. This
approach was also used for IC measurements made with clinical SABR spine plans detailed in
chapter 4.
Figure 3.14: Determination of a homogeneous region from looking at the 98% and 102% iso-
doses. Left) the anterior point of IC placement is in a homogeneous region in MattL, determined
by looking at 98% and 102% of the dose to this point of 11.02 Gy for patient 4. Right) The lat-
eral point of ionisation chamber placement is not in a homogeneous region in MattL, determined
by looking at 98% and 102% of the dose to this point of 5.07 Gy.
Film Absolute Dose Measurements
Using the reference markings (figure 3.13), pin-pricks were made on film taped onto the removable
perspex blocks (figure 3.15). This ensures the correct alignment of film in the scanner so the 2D
planar dose distribution measured is compared to the correct dose distribution selected from the 3D
DICOM dose cube exported from RayStation.
A sheet of film from a box of GAFchromic EBT3 film (all from the same batch) purchased for use in
this study was divided into eighteen small sections. The sections were pre-irradiated with varying
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Figure 3.15: Left) pinpricks made on a section of film taped on the removable perspex block.
Right) pin-pricks identifiable on the film scan.
radiation dose (0 - 3455 cGy) and scanned 24 hours later using an Epson Expression 10000XL
flatbed scanner. A spatial resolution of 75dpi (which reduces noise by raw data averaging) and no
image processing was performed on these scans that were saved in uncompressed (TIF) format [80].
Calibration curves were created by fitting scan response points (corresponding to the optical density
of each film section) to an exponential equation in SNC Patient software (figure 2.29). As the film in
this box were from the same batch, little variation in the sensitive layer thickness that may influence
the film response to radiation was assumed [81]. Hence, this calibration curve was applied to each
sheet of film contained in the box if scanned 24 (±1) hours following irradiation (minimising
time-dependent variations in film response). Application of the calibration curve converts the film
response (optical density of a particular section) to absolute dose. Once calibrated to absolute dose,
the film was then compared to a DICOM dose cube exported from RayStation, by loading both into
SNC Patient Software and using SNC’s gamma analysis functionality (described further below).
For validation measurements, absolute dose measurements with gamma criteria of 1%/1mm,
2%/1mm and 2%/2mm were recorded. The 1%/1mm gamma criteria is considered strict criteria for
comparing dose distributions in terms of both the dose difference and distance to agreement. During
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gamma analysis a translation of up to 1 mm in longitudinal, lateral or axial directions was allowed
due to uncertainties in geometric alignment (section 3.1.4). A scaling factor of 0.95 to 1.05 was
allowed to account for variations in film response due to processing uncertainties (e.g. variations in
film induced by temperature, handling or processing factors).
3.1.4 Validation
Once MattL was produced, it was validated to ensure it matched the design specifications and was
appropriate for use. To start with, MattL was scanned in a Siemens SOMATOM Sensation CT
scanner at ACH with 1 mm slice width which is in accordance to departmental spine SABR
protocols. These CT scans were imported into RayStation, where the phantom geometry was
measured to ensure this matched the design specifications. This included checking that IC and film
measurements were appropriately aligned to the phantom’s geometric centre. Following this,
perspex, PVC, liquid water and metal implant materials were contoured on the CT scans in
RayStation. Suitable density over-ride values were chosen and validated with dose measurements.
These validation processes are described in the next subsections.
Alignment to Geometric Centre
The geometric alignment of the central cube insert to the exterior markings used of MattL was
validated by taping metal BBs (diameter 1.0 mm) to the external shell of MattL (figure 3.16). A
point of interest (POI) was placed on the CT images of MattL imported into RayStation, to intersect
the external BBs (figure 3.18). This POI was centred at the geographical centre of MattL and
expanded to a large volume to confirm the central IC hole was aligned to MattL’s geographical centre
(figure 3.17). Therefore the 0.04cc IC active volume, when placed in the central IC hole, aligns to
the geographical centre of MattL with an uncertainty of ±0.7 mm. This uncertainty was calculated
from the uncertainties for CT slice thickness (0.5 mm) and radius of the BB (0.5 mm), combined in
quadrature according to equation 3.1 [82]. The distance between the lateral, posterior and central IC
hole, measured on CT images matched the actual measurement on the removable centre
heterogeneous blocks (figure 3.18). The distance from the central IC hole to edge of the block (i.e.
position of the film plane) also matched actual measurements on the removable centre heterogeneous
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blocks to within a 0.7 mm accuracy. This uncertainty is based on the uncertainty in the CT image
slice width (0.5 mm) and physical measurement (0.5 mm) added in quadrature (equation 3.1) [82].
σA =
√
σB2 + σC2 (3.1)
Figure 3.16: BBs stuck onto external markings of MattL, aligned to CT isocentre using the CT
bore internal lasers.
Figure 3.17: A large diameter POI (labelled CT Ref) placed on CT scans imported into RaySta-
tion of MattL with BBs taped onto MattL’s external markings which coincides with MattL’s
geometric centre. The POI was aligned to intersect the external BBs and intersected the loca-
tion of the active volume of an ionisation chamber, when inserted into the ionisation chamber
holes (maroon circles).
Lengths of wire (diameter = 0.5 mm) were taped onto film reference markings made on the
removable perspex blocks so these can be identified on the CT images in RayStation (figure 3.19).
From the CT images, an assessment was made to ensure the reference markings (identified by the
wire pieces) were aligned to the external BBs with an uncertainty of ±0.6 mm. This uncertainty is
based on the uncertainty in the wire radius (0.25 mm) and physical measurements (0.5 mm) added
in quadrature (equation 3.1).
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Figure 3.18: Distance measured between the central IC hole and lateral IC hole on the virtual
model of MattL. Expected distance between these IC holes based on actual measurement was
3.8 cm. Note: The resolution of the CT image limited the centering of ROIs on the IC holes.
Figure 3.19: Left: Soldering wire stuck onto markings on the anthropomorphic phantom perspex
blocks used to pinprick film. Right: CT image of the anthropomorphic phantom with BBs stuck
onto the anthropomorphic phantom external markings and wires visible.
3.1.5 Virtual Model of MattL
The CT image data of the MattLTi, MattLPVC and MattLperspex were imported into RayStation to
create a virtual model of these versions of MattL. Due to metal artifacts in the CT image, ROIs for
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each material were contoured so a density over-ride can be applied to these (for example, metal and
water ROIs in figure 3.20 & 3.21). IC and film measurements were taken to assess the accuracy of
density over-ride value used for each material contoured.
Figure 3.20: Metal ROI (violet) contoured on the virtual model of MattL.
Figure 3.21: Metal (violet) and liquid water (cyan) ROIs contoured on the virtual model of
MattL.
ROIs corresponding to the active volume of the IC inserted into one of the three IC holes were
contoured on the CT images of MattL in RayStation (figure 3.22). The volume of these ROIs was
0.04 cm3 which is the active volume of the 0.04 cc Iba IC [16]. The placement of these ROIs was
validated by comparing the distance between IC ROIs measured in RayStation and actual distance
between IC holes on the interchangeable central blocks (figure 3.18). Plans were calculated on MattL
in Raystation, aligning the plan isocentre to the centre of the central IC (which is also the
geographical centre of MattL). For this study, dose in RayStation was calculated by applying a 1
mm x 1 mm x 1 mm dose grid resolution.
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Figure 3.22: Ionisation chamber point doses contoured as ROIs in the virtual model of the
MattL phantom.
Density Over-ride Value of Materials
The upper limit of the CT electron density table for the Siemens SOMATOM Sensation CT scanner
used at ACH is 2.88 g cm-3. This CT scanner required a density over-ride for liquid water, perspex,
PVC and metal ROIs to correct for metal artifact introduced by the metal implants in MattLTi
(figures 3.20 & 3.21) [24,30]. These were contoured by applying a threshold with an appropriate
window and level for the material of interest and verifying the ROI dimensions matched physical
measurements of MattL. The density over-rides were validated by comparison of dose measured with
the IC and film to the dose calculated in RayStation with simple square fields and more complex,
VMAT plans. The VMAT plans were designed for coverage of a spherical PTV of 4 and 6 cm
diameter with the plan isocentre at the central IC position.
Previous work at ACH established the density over-ride validated for perspex in PhilM to be 1.105 g
cm-3. The manufacturer quoted mass density for PVC was 1.36 g cm-3 and clinically, the density
over-ride used at ACH for titanium implants is 4.454 g cm-3. These density over-ride values were
validated by comparing absolute dose measurements with the dose calculated in RayStation with
virtual MattL models. Density over-ride values above and below these values were also investigated
to optimise the density over-ride values used in the virtual model of MattL. As a very small section
of the chromium cobalt rod is used in MattTi (compared to amount of titanium) a single density
over-ride value was given to the entire section of the metal implant.
The most appropriate density over-ride values to use for perspex, PVC, and metal implants were
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validated in succession, by comparing IC and film absolute dose measurements of dose calculated in
RayStation in MattLperspex, MattLPVC and MattLTi respectively. Due to the limited amount of film
available for this project, measurements were completed on particular plans in MattLTi and
MattLPVC (table A.9). Relative and absolute dosimetry were acquired in MattL and compared to
Raystation planned dose to verify the density over-ride applied allows absolute dosimetry with film.
3.2 Results
The validation of MattL required a large number of IC and film measurements that can be found in
Appendix A. These compared the dose calculated in RayStation to the measured dose to optimise
the virtual model of MattL used later in this study (chapter 4). Determination of key parameters to
use for absolute dose measurements with the ion chamber are detailed in subsection 3.2.1, while the
density over-ride values selected for use in this study are presented in subsection 3.2.2.
3.2.1 Ionisation Chamber Absolute Dose Measurements
The ND,W,Q0 for the 0.04cc chamber determined from cross calibration was 0.962 mGy nC
-1 [58].
There was minimal effect of dose rate on calibration factors, ks and kpol ( table A.1). Considering
that the SABR spine treatments at ACH utilise a 6 MV FFF beam and dose rates higher than
conventional treatments (>600 MU min-1), the derived values of ks = 1.008 and kpol = 1.003 were
suitable for use in this study.
Absolute dose measurements in MattL (section 3.1.3) and SABR spine plan measurements (chapter
4) were made according to equation 3.2. This equation is modified from equation 2.19 where for a 6
MV FFF beam energy, ks = 1.008, kpol =1.003, kQ,Q0 = 0.995 [83] and kelec = 1 as the electrometer
used for measurements is the same electrometer used for cross calibration of the 0.04cc Iba IC. The
variation in beam output at the time of measurement as well as the environmental pressure and
temperature correction, kTP (equation 2.18) were also taken into account in equation 3.2.
Dw(Gy) =
(ND,w,Q0 kQ,Q0 kpol kelec ks)M1 kTP
1 +Beam Output V ariation
=
0.968M1 kTP
1 +Beam Output V ariation
(3.2)
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Where DRayStation is the point dose calculated in RayStation and MMattL is the point dose measured
at the same location in MattL. This assesses the accuracy of dose as calculated in RayStation.
3.2.2 Density Over-Ride Value of Materials
The density over-ride value for each material (table 3.3) was complicated to validate due to the
range and number of measurement results. These dose measurements and RayStation calculated
doses can be found in section A.2 of Appendix A.
As SABR utilises multiple beam angles, similar to VMAT plans, the VMAT plan had greater
relevance in this study. Furthermore, since the diameter of the cylindrical section of PVC is 5 cm,
the results of the VMAT plan with spherical PTV of 6 cm were considered more relevant for
assessment of the phantom as a greater section of the heterogeneous centre block is irradiated. This
is evident as the 100% isodose (normalised to the dose prescribed) is delivered to the entire volume
of metal implants in the 6 cm spherical PTV VMAT plan in figure 3.24 compared to only part of the
metal implant in the 4 cm spherical PTV VMAT plan in figure 3.23. Furthermore, a higher dose for
the 6 cm spherical PTV VMAT plan (approximately 80% of the prescribed dose = 4.56 Gy) would
be delivered to film (placed next to the interchangeable central block) as compared to the 4 cm
spherical PTV VMAT plan (approximately 60% of the prescribed dose = 3.42 Gy), improving the
signal to noise ratio. IC dose measurements were only performed for simple fields and not VMAT
plans for the perspex over-ride values of 1.100 g cm-3 (table A.4) and 1.115 g cm-3 (table A.5). This
was because the percentage deviations of the point dose for these density over-ride values were no
better than those resulting from a density over-ride value of 1.105 g cm-3 (table A.2).
Ionisation Chamber Measurements
The density over-ride values in table 3.3 were validated from the ∆DIC. Overall, the percentage
difference in RayStation calculated point doses with these density over-ride values agree with the
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Figure 3.23: Dose distribution of dose delivered to MattLTi with the 4 cm spherical PTV VMAT
plan as calculated in RayStation. The 100% isodose (red) does not completely cover the metal
implants contoured in blue.
Figure 3.24: Dose distribution of dose delivered to MattLTi with the 6 cm spherical PTV VMAT
plan as calculated in RayStation. The 100% isodose (red) completely covers the metal implants
contoured in blue.
measured dose to within ± 3% or ± 0.3 Gy (table A.2, A.6 and A.8). This is similar to the
percentage difference criteria for absolute point dose measurements used in patient specific QA at
ACH (figure 3.25). The agreement of dose measurements with the RayStation calculated dose
(∆DIC) with other density over-ride values (A.3, A.4, A.5 & A.7 in Appendix A) did not show a
greater agreement to the ∆DIC results when density over-ride values, listed in table 3.3 were used.
Hence, the density over-ride values in table 3.3 were valid for use in the virtual model of MattL.
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Material Tissue material Mass Density in
is replicating RayStation (g cm-3)
Perspex soft tissue 1.105
PV C vertebral bone 1.36
liquid water soft tissue 1
metal implants N/A 4.454
Table 3.3: Mass density over-ride values applied in RayStation to anthropomorphic phantom
materials.
Figure 3.25: Percentage difference criteria comparing the absolute dose measurement with an
ionisation chamber to the point dose calculated in RayStation used in patient specific quality
assurance for spine SABR treatments at ACH.
Film Measurements
Relative and absolute gamma analysis of film measurements in SNC patient produced very similar
results, as seen in figure 3.26. This verifies that the virtual model of MattL in Raystation is
appropriately modelled with the density over-rides applied allowing for accurate absolute dose film
measurements in the phantom.
The absolute dose film measurements of MattL compared to the RayStation calculated dose (with
density over-ride values as in table 3.3) can be found in table A.9. From these results the overall
result and results from the 6 cm PTV spherical VMAT plan are given in table 3.4.
Absolute Dose Gamma Pass Rate
Gamma Criteria:
Plan Type 1%/1mm 2%/1mm 2%/2mm
Overall > 50.0% > 73.0% > 85.0%
6 cm PTV Sphere VMAT ≥ 80.0% > 93.0% > 99.0%
Table 3.4: Results from film measurements.
Based on the 2%/1mm and 2%/2mm gamma pass values, the dose distribution measured with film is
in agreement to the dose calculated in the virtual model of MattL with the density over-ride values
(table 3.3) selected from IC measurements described in the previous subsection.
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Figure 3.26: Comparison of absolute (AD) and relative dosimetry (RD) gamma analysis of film
measurements in MattL during performed during validation.
3.2.3 Summary
A robust anthropomorphic phantom, MattL pushed the limits of what can be constructed from the
clinical engineering team. Fortunately, this researcher was able to liaise directly with ACH’s clinical
engineering department to precisely engineer MattL to match the design brief. This was challenging
to produce accurately while ensuring the structural integrity of MattL was not compromised.
Consequently this required over a year of work (>100 hours) to complete. MattL was designed and
validated for determining the accuracy of RayStation generated radiotherapy plans for use in this
thesis. The MattL phantom has been precisely engineered for versatile positioning of dosimeters and
contains surgical grade metal implants. A virtual model of MattL was created in RayStation from
CT scan images and validated for use by selecting appropriate phantom material density over-ride
values listed in table 3.3. Further discussion on MattL can be found in section 5.1. Based on the
agreement between dose measurements and the virtual of MattL in RayStation, film measurements
with a 2%/2mm and 3%/1mm gamma criteria and IC dose measurements with an associated
uncertainty of ±3% are suitable to investigate the agreement of dose measurements in MattL and
dose estimated in RayStation for SABR treatments. The use of MattL for this purpose is presented
in chapter 4.
Chapter 4
SABR Spine Plan Measurements
Chapter 3 detailed the design and construction of a phantom for dose measurement of SABR spine
treatment plans with and without metal. This was considered the first major component of work
presented in this thesis. This chapter details the second major component of work undertaken. In
this chapter we define the methodology to use MattL as a tool for evaluating the RayStation
calculated dose compared to dose measurements performed in MattLTi and MattLPVC. Section 4.2
presents the results from this, followed by the statistical analysis of these results.
4.1 Methods
Eight SABR spine treatment plans, randomly selected from a list of clinical patients who had
completed this treatment at ACH were anonymised and recalculated using RayStation’s CCC
algorithm on virtual models of MattLPVC and MattLTi (section 3.1.5). The dose delivered from
these treatment plans was measured with IC and film placed in MattLPVC and MattLTi on the
Elekta Versa HD linac treatment unit, as described in the next subsection. Statistical analysis of
these results was carried out in R (R Foundation for Statistical Computing, Vienna, Austria) [84]




MattLPVC and MattLTi were placed on the treatment couch using the metal lock bar (see figure 3.7).
The external markers of MattL were then aligned to the external lasers by translation of the
treatment couch. This aligns the geometric centre (and central IC hole location) of the phantom to
the machine isocentre. Historical spine SABR treatment plans utilised in this project were planned
using inverse planning methods and the collapsed cone convolution (CCC) dose calculation
algorithm in RayStation. These spine SABR plans were randomly selected from a list of spine SABR
patients that had completed treatment at ACH. They were then anonymised, removing any patient
identifiers prior to use in this research. Hence, ethics approval was not necessary according to the
Auckland Health Research Ethics Committee. IC and film measurements of these plans were carried
out using the 0.04cc IC and GAFchromic EBT3 film as described in section 3.1.3.
Ion Chamber Comparisons
Absolute dose measurements performed with the 0.04 cc IC placed in the anterior, lateral and
central positions of MattLPVC and MattLTi (as in figure 3.10) were compared to the dose calculated
in RayStation as in equation 3.3. The difference between these comparisons were calculated as
∆DIC (MattLTi-MattLPVC)(%) = ∆DIC MattLTi(%)−∆DIC MattLPVC(%) (4.1)
Where ∆DIC MattLTi and ∆DIC MattLPVC is the percentage difference of dose measured relative to
dose calculated in RayStation in MattLTi and MattLPVC respectively.
Data were plotted on appropriate graphs to identify the spread and correlation between
measurements made in MattLPVC and MattLTi. A Pearson test was used to quantitatively assess
correlation [20,66,84].
Gamma Criteria
Film was placed in posterior and lateral positions (as in figure 3.10). Considering the gamma criteria
used clinically at ACH (figure 4.1), a 2%/2mm and 3%/1mm gamma criteria were used for absolute
dose measurements of the SABR spine plans in MattL. A 3%/1mm gamma criteria was pivotal in
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this research to assess for a high alignment accuracy required for SABR treatment methods due to
the close proximity of the spinal cord PRV to the PTV.
Figure 4.1: Gamma criteria comparing the absolute dose measurement with film to the dose
distribution calculated in RayStation used in patient specific quality assurance for spine SABR
treatments at ACH.
The gamma values of film measurements with metal compared to without metal, γ(MattLTi-MattLPVC),
were calculated by
γ(MattLTi-MattLPVC)(%) = γMattLTi(%)− γMattLPVC(%) (4.2)
Where γMattLTi and γMattLPVC is the gamma value resulting from gamma analysis comparing the
calibrated film measurement to the dose distribution exported from RayStation for MattLTi and
MattLPVC respectively.
4.1.2 Statistical Analysis
A TOST (as described in section 2.5.3) was performed to statistically analyse and compare the dose
accuracy as calculated in RayStation (equation 3.3 and SNC gamma analysis) in MattLTi and
MattLPVC. This was performed by constructing the 90% CI from the average of bootstrapped
samples obtained from the eight data points of ∆DIC (MattLTi-MattLPVC) (following equation 4.1) and
γ(MattLTi-MattLPVC) (following equation 4.2), for each measurement location and type. That is, IC
measurements at the centre, lateral and posterior positions as well as film in lateral and posterior
positions with 2%/2mm and 3%/1mm gamma criteria. This analysis was conducted in R (R version
3.6.3., The R Foundation for Statistical Computing, Vienna, Austria) [84]. The R script used to
carry out the bootstrap re-sampling that uses the ‘boot()’ and ‘boot.ci()’ functions available from
the ‘boot’ package to calculate the average of bootstrapped “resampled” samples can be found in
Appendix B.2.1.
The equivalence margin for the TOST used in this study to test for equivalence of ∆DIC MattLTi and
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∆DIC MattLPVC was ±3%. This equivalence margin was chosen by considering the ∆DIC to validate
the density over-ride values used for the virtual model of MattL in RayStation were within ±3%.
Hence, the null hypothesis, H0 and alternative hypothesis HA tested for the TOST used for IC
measurements in this study are
H0,IC : µδ < −3% OR µδ > +3% (4.3)
HA,IC : −3% < µδ < +3% (4.4)
Where µδ is the average difference between data sets as calculated by equations 4.1 and 4.2. The CI
(with 90% confidence level), obtained from bootstrapped samples was compared to the equivalence
margin ±3% as in equation 4.3 & 4.4. Equivalence was assumed upon rejection of H0, in favour of
HA if the lower confidence limit was larger than -3% and if the upper confidence limit was lower than
+3% (equation 4.4 & figure 4.2). Conversely, when H0 was rejected, non-equivalence between data
was assumed.
Figure 4.2: The interpretation of the TOST results for comparing ionisation measurements to
the dose estimated in RayStation used in this study (∆DIC). The null hypothesis is rejected
in favour of the alternative hypothesis, that there is equivalence between data for samples R1
- R4, with a CI that falls withing the equivalence margin of -3% and +3% (green). The null
hypothesis, that the data is not equivalent is accepted for samples R5 - R7, with a CI that falls
outside the equivalence margin of -3% and +3% (red).
The equivalence margin for the TOST used in this study to test for equivalence of γ(MattLTi-MattLPVC)
was ±5% (equations 4.5 & 4.6). This equivalence margin was chosen as we allow a 0.95 to 1.05 (5%)
scaling factor for variations in film response (as noted in section 3.1.3).
H0,film : µδ < −5% OR µδ > +5% (4.5)
HA,film : −5% < µδ < +5% (4.6)
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4.2 Results
Dose measurements and the RayStation calculated dose were used to assess the accuracy of
RayStation in calculating dose with and without metal. This included statistical analysis of the data
to answer one of the main aims of this project. That is if the presence of metal in the patient
impacts the accuracy of RayStation’s prediction of dose delivery. This section presents the results
and assessment of data gathered in this research, used to investigate the dosimetric impact of
metal-ware in-situ for SABR spine treatments.
4.2.1 Dose Measurements
MattL was placed on the Elekta Versa HD treatment linac unit couch top, aligning its geometric
isocentre to the linac isocentre using MattL’s external markings (figure 3.7). A statistical comparison
of the data including a levene’s test and Pearson correlation test was performed (described in section
2.5.1 & 2.5.2). Further statistical analysis that aims to investigate the aims of this thesis research
are given in the next subsection. The complete set of dose measurements of the eight SABR spine
treatment plans performed in this project can be found in section B.1 of Appendix B.
Ionisation Chamber Measurements
The reproducibility of the dose calculated in RayStation from the percentage difference to the
measured dose in both MattLPVC and MattLTi showed some variance, where the majority of the
∆D(%) results were within a range of ±10% (figure 4.3). These large differences between the
measured and calculated dose were due to steep gradients and consistent between MattLPVC and
MattLTi. The levene’s test returned a p-value of 0.9329, well above the significance level of 0.05
required to conclude that there is equal variance between ∆DIC MattLTi and ∆DIC MattLPVC . While
there is no observable difference in the spread of ∆DIC results for the central and lateral IC
measurements locations in figure 4.3, all the ∆DIC results in the anterior IC location (pink data
points) were positive in both MattLPVC and MattLTi. There is evidence of variation in ∆DIC from
paired box plots linking pairs of measurements made from the same SABR spine patient plan, within
different phantoms, MattLPVC and MattLTi. These paired data points are linked with grey lines in
4.2. Results 77
Figure 4.3: Distribution of percentage deviation of ion chamber measurement compared to dose
calculated in RayStation. Lateral jitter of data points has been added to visualise each data
point.
figures 4.4 - 4.6. In these figures, a few of the grey lines are horizontal, suggesting the individual
paired data points have the same/similar ∆DIC. Conversely, non-horizontal grey lines in these
figures suggest non-equivalence between individual paired data points. Hence there is no clear trend
in these results, suggesting some random variation in the data. Measurement uncertainties
introduced by the placement of the IC in a high dose gradient was likely. Due to this limitation, it
was important that film measurements were utilised in this work.
The correlation coefficient determined from the Pearson correlation test, R= 0.86 and p value of 6 x
10-8 suggests there is a strong positive relationship between IC measurements made in MattLPVC
and those made in MattLTi (figure 4.7). This is as expected, as paired measurements are made at
the same location in the MattL phantom with the same SABR spine treatments delivered. This
indicates that the predominant reason for non-zero values of ∆DIC is due to the plan and/or
measurement uncertainty and not due to the presence of metal.
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Figure 4.4: Box-plot of paired data points corresponding to percentage deviation of ionisation
chamber measurements (∆DIC) in the central location to dose calculated in RayStation.
Figure 4.5: Box-plot of paired data points corresponding to percentage deviation of ionisation
chamber measurements (∆DIC) in the lateral location to dose calculated in RayStation.
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Figure 4.6: Box-plot of paired data points corresponding to percentage deviation of ionisation
chamber measurements (∆DIC) in the anterior location to dose calculated in RayStation.
Figure 4.7: Scatter plot of ion chamber measurements (∆DIC) made in MattLPVC and MattLTi.
The Pearson correlation coefficient (R value) was calculated to determine if there is a statistical
relationship between these variables.
Film Measurements
Relative and absolute gamma analysis of film measurements of SABR spine treatment plans carried
out in SNC Patient software produced very similar results, as seen in figures 4.8 & 4.9. This further
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validates that the virtual model of MattL in Raystation is appropriately modelled with the density
over-rides selected during phantom validation (section 3.2.2). From the spread of data displayed on
Figure 4.8: Comparison of absolute (AD) and relative dosimetry (RD) gamma analysis of SABR
spine treatment plans measured with film in MattLPVC.
Figure 4.9: Comparison of absolute (AD) and relative dosimetry (RD) gamma analysis of SABR
spine treatment plans measured with film in MattLTi.
the plot of film measurements in figure 4.10 the results with a 2%/2mm gamma criteria are better
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(i.e. closer to 100%) than results with a 3%/1mm gamma criteria. This suggests that with a
2%/2mm criteria for gamma analysis, the RayStation calculated dose in the virtual model is in good
agreement to the dose distributions measured with film. The levene’s test returned a p-value of
0.8779, well above the significance level of 0.05 that is required to conclude that there is equal
variances between the ∆DIC MattLPVC and ∆DIC MattLTi is assumed.
;
Figure 4.10: Distribution of gamma values from film measurement gamma comparison to dose
calculated in RayStation. Lateral jitter of data points have been added to visualise each data
point.
Similar to the paired box-plots of IC measurements (figure 4.4 - 4.6), the paired box plots for film
show no clear trend in paired gamma values that compare the dose distribution as calculated in
RayStation and measured in film placed in MattLPVC and MattLTi. The Pearson correlation
coefficient of R=0.57 (and p value of 6 x 10-4) determined in figure 4.15 suggests there is a
moderately positive relationship between these film measurements, as is expected from
measurements of the same SABR spine treatment plans delivered with and without metal.
From figure 4.7 it is also evident that the ∆DIC between the dose measurements and RayStation
calculated dose is similar in MattLTi as is in MattLPVC. This is compelling as this suggests the
∆DIC could be attributed to the complexity of the treatment plan, setup inaccuracies, measurement
at a hot or cold spot and not due to the accuracy of RayStation in handling metal.
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Figure 4.11: Box-plot of paired data points corresponding to gamma values (γ) comparing film
measurements in the posterior location to dose calculated in RayStation with a gamma criteria
of 3%/1mm.
Figure 4.12: Box-plot of paired data points corresponding to gamma values (γ) comparing film
measurements in the posterior location to dose calculated in RayStation with a gamma criteria
of 3%/1mm.
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Figure 4.13: Box-plot of paired data points corresponding to gamma values (γ) comparing film
measurements in the lateral location to dose calculated in RayStation with a gamma criteria
of 3%/1mm.
Figure 4.14: Box-plot of paired data points corresponding to gamma values (γ) comparing film
measurements in the lateral location to dose calculated in RayStation with a gamma criteria
of 2%/2mm.
84 Chapter 4. SABR Spine Plan Measurements
Figure 4.15: Scatter plot of gamma values from gamma analysis of film measurements made
in MattLPVC and MattLTi. The Pearson correlation coefficient (R value) was determined to
determine if there is a statistical relationship between these variables. Note: Horizontal error-
bars have been omitted for clarity.
4.2.2 Statistical Analysis
The true value of the difference in the measured dose compared to dose calculated in RayStation
with and without metal lies within the stated CIs in table 4.1 with a 90% confidence level. From the
90% CI of bootstrapped samples of dose measurements, listed in table 4.1, overall the null hypothesis
is rejected in favour of the alternative hypothesis, that the data sets are equivalent. The one
exception to this is the film measurement in the posterior location with a 3%/1mm gamma criteria.
The 3%/1mm criteria is strict on geometric accuracy of measurements which would have pushed the
upper limit of the CI just outside the equivalence margin for the TOST. The true value of the
difference in the measured dose compared to dose calculated in RayStation (i.e. accuracy of the
RayStation calculated dose) with and without metal lies within the stated CIs in table 4.1 with a
90% CI.
4.2.3 Summary
The anthropomorphic phantom, MattL, created in the first part of this thesis work (detailed in









Centre (-0.74, 2.08) -0.008 0.86 Yes
Anterior (-0.69, 0.56) 0.003 0.38 Yes
Lateral (-0.59, 2.71) 0.009 1.01 Yes
Film Posterior (-2.76, 4.69) 0.024 2.22 Yes
(Gamma: 2%/2mm) Lateral (-4.03, 1.20) -0.033 1.60 Yes
Film Posterior (-4.21, 5.09) -0.019 2.85 No
(Gamma: 3%/1mm) Lateral (-3.71, 3.34) -0.013 2.21 Yes
Table 4.1: CI (90 % confidence level) from bootstrapped samples of ionisation chamber and
film measurements of absolute dose-to-water in MattLPVC from MattLTi.
The measured dose was compared to the dose calculated in RayStation to determine the accuracy of
RayStation’s CCC dose calculation algorithm in estimating dose in the presence of metal. The CCC
dose calculation algorithm was able to estimate dose when metal-ware is within the vicinity of the
treatment region to when metal-ware is not present in the treatment region equivalently to within a
±3% difference for IC and ±5% difference for film measurements.
Chapter 5
Discussion
Following the work carried out to develop and validate the anthropomorphic phantom MattL,
described in chapter 3, this was used to measure dose from spine SABR treatment plans with and
without metal as presented in chapter 4. While the results of this work are given in the
aforementioned chapters, this chapter provides further discussion, interpretation and application of
these results. Section 5.1 predominantly focuses on the production process of MattL and section 5.2
focuses on the results from measuring spine SABR plans with MattL.
5.1 Phantom
An anthropomorphic phantom, MattL was designed and produced for assessing accuracy of dose
delivery to spine SABR patients with metal implants. MattL is a versatile phantom that can be used
to make dose measurements in a number of locations within the phantom with both IC and film, with
and without metal spinal implants. A virtual model of MattL was created in RayStation from CT
scan images and validated for use by selecting appropriate phantom material density over-ride values
listed in table 3.3. This section discusses the results of the validation process that is based on IC and
film measurements and explains some of the challenges faced during the design process of MattL.
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5.1.1 Recommendations for the use of MattL
MattL was made to the design specifications for geometric centre, chamber positioning and
geometric dimensions to within 0.7 mm. The IC dose measurements performed in MattL accurately
determined the dose estimated in the virtual model of MattL (i.e. the ∆DIC) to within ±3%. Due to
metal artifacts present in CT images used to create a virtual model of MattL in RayStation, suitable
density over-ride values in table 3.3 were selected for use in this virtual model by comparing IC and
film measurements to dose calculations made on the model of MattL in RayStation. The
recommendation made by AAPM Task Group (TG) 85 is for a 2-3% accuracy in dose delivery for
inhomogeneities determined through transmission measurements through low density inhomogeneity
(e.g. lung). While transmission measurements were not appropriate here, due to the small size of the
inhomogeneity (metal implant), the ±3% ∆DIC results meets the expectation in this
recommendation. Hence, the 3% uncertainty in IC measurements is acceptable for MattL, proving it
is a valuable tool in the development and understanding of the dosimetric impacts of metal in SABR
spine treatments.
From these results gamma criterion of 2%/2mm and 3%/1mm are recommended to assess the
agreement of film measurements to the RayStation calculated dose, as overall a >85% for the
2%/1mm gamma pass rate in simple field and VMAT plans was achieved (table 3.4). As there was
less agreement between film measurements and dose calculated in RayStation with the gamma
criteria of 2%/1mm and 1%/1mm these criteria may be too strict for film measurements in MattL.
However, as SABR spine treatments are highly conformal it is important to investigate the geometric
precision of dose distribution measured in film as compared to those calculated in RayStation. An
appropriate gamma criteria for this is 3%/1m, which is more relevant for SABR spine treatment
plans as this criteria relaxes the dose difference parameter but has a more restrictive criteria for the
DTA to ensure spatial accuracy is achieved. The device has the potential for PSQA for SABR spine
plans where metal is a concern. The 2%/2mm gamma criteria with a 85% tolerance level may be
useful for this but the tolerance level for the 3%/1mm gamma criteria would require more
investigation. The suggested 85% tolerance level is based on the SABR spine treatments investigated
in this thesis, hence is different to what is currently used in PSQA of spine SABR treatments at ACH
(figure 2.31). For PSQA, an investigation level higher than 85% may be advantageous to identify
plans that may have some discrepancy in dose distributions measured to the dose distribution
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calculated in RayStation and further investigate if these plans are appropriate for clinical
treatments. This conservative approach may ensure patient safety to improve treatment outcomes.
5.1.2 Challenges
While limitations in resources restricted the design of the anthropomorphic phantom produced in
this project, a number of other challenges were also faced in the design process. These are described
in the next subsections.
Initial Design
Initial designs of the phantom did not include the central water box cube as described in section
3.1.2. Instead, a design that embedded the PVC cylinder (diameter 5 cm) and metal in resin was
attempted, however while the epoxy resin was setting in the production process, the block
temperature reached >200°C. This lead to the expansion of the metal implants within the relatively
brittle, set resin causing the block to crack (figure 5.1). As only 6 titanium screws were donated for
use in this project and ideally 4 were needed to replicate a posterior spine fixation, the metal
implants were salvaged from the cracked resin block. Fortunately, only one of the titanium screws
were damaged during this process so 5 screws were still available for use to mimic a posterior
fixation of the spine in later designs (figure 1.1). In subsequent designs, the use of this resin with
metal implants was avoided to prevent further damage to the remaining titanium screws available for
use in this project. Therefore a ‘water-box’ block was chosen.
Figure 5.1: Left) A crack in the resin block during production of initial MattL designs. Right)
Damage to a titanium screw when trying to salvage materials from the cracked resin block.
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Absolute Dose Measurements in Non-Water Materials
Following IAEA TRS 398, the 0.04 cc Iba IC was cross calibrated for absolute dose measurements in
water by determination of ND,W,Qo as 0.962 mGy nC
-1 by a PSDL, the Institute of Environmental
Science and Research (ESR). In this study, the use of the IC when placed in the central PVC
position in MattLPVC and MattLTi to measure the absorbed dose-to-water is problematic as the
chamber has been calibrated for absorbed dose-to-water measurements. For 6 MV photons, the
energy of secondary electrons is approximately 1.8 - 3.0 MeV [85,86]. For electrons with this kinetic
energy, the distance traversed (the range of continuous slowing down approximation, RCSDA) is
<0.979 cm in water [2]. The penetration distance i.e. the average distance, R of light charged
particles is less than RCSDA (figure 5.2). As R < RCSDA = 0.979 cm the majority of secondary
electrons created in the liquid water or perspex sections surrounding the PVC section (diameter = 5
cm) of MattLPVC or MattLTi do not reach the IC for measurement. The IC therefore is
predominantly measuring charge created in its active volume that results from transference of energy
from secondary electrons created in the PVC section - that is, absorbed dose-to-PVC and not
absorbed dose-to-water. This is problematic as the chamber has been cross calibrated for absolute
dose-to-water measurements and not absolute dose-to-PVC measurements. The need to convert
dose-to-medium to dose-to-water (and vice versa) is currently under debate in the medical physics
community, given the options for reporting dose as dose-to-water or dose-to-medium in modern
TPS [87,88]. A main argument for the use of dose-to-water reporting is the historical use of this to
design treatments based on radiobiological research using dose-to-water values [88].
Figure 5.2: Range of a light charged particle in terms of continuous slowing down approxima-
tion, RCSDA and average range, R. The RCSDA represents the path of the particle’s trajectory
and not necessarily the depth of penetration. Modified from Podgorsak [2]
The literature suggests the use of stopping power ratios to convert from dose-to-medium to
dose-to-water (and vice versa) [89]. This concept is also utilised in Monte Carlo dose calculations as
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a post processing step to convert dose-to-water to dose-to-medium [5,90,91]. However, there are
some that advise against the use of the stopping power ratio for this conversion [87] or the use mass
energy absorption ratios instead [85]. Ultimately, as there is no standardised guidance on the
introduction of a correction factor to convert dose-to-water to dose-to-PVC, whether this is through
the application of stopping power ratios or the ratio of mass attenuation coefficients, this would add
further uncertainty to absolute dose measurements with the ion chamber. As the dose calculated in
RayStation is reported in terms of dose-to-water in medium Dw,m a correction factor to convert
dose-to-water measurements to dose-to-medium was not required to be added to equation 3.2.
5.2 SABR Spine Plan Measurements
Overall, the results from SABR spine measurements with metal (i.e. measurements in MattLTi)
show an equivalence with SABR spine measurements without metal (i.e. measurements in
MattLPVC) to within ±3% for IC and ±5% for film measurements (the equivalence margins used in
the TOST). This suggests that the dose calculation accuracy in the RayStation treatment plan for
SABR spine patients with metal-ware in-situ is equivalent (to within ±5%) to those without
metal-ware in-situ. This means it may be suitable to calculate dose for SABR spine treatments for
patients at ACH who have metal implants posteriorly fixed to the spinal vertebrae to within an
acceptable degree of accuracy.
This agrees with a study by Cheng [26] that suggests the dose effect of metal to the spinal cord and
the tumour volume is not observable and the AAA and ACUROS dose algorithms have acceptable
accuracy for spinal SABR (with a 95% tolerance for the gamma value with 3%/3mm gamma
criteria) [26]. A Monte Carlo (MC) simulation study by Redmond [24] reports approximately 6%
underestimation of radiation dose to structures in front of high density titanium hardware due to
electron back-scatter. Considering MC is regarded as a gold standard for dosimetry, we would expect
the dose measured in locations in front of MattL’s SpineArt metal implants to be 6% higher than
that estimated in RayStation [30]. The Redmond study also anticipated that the dose is
approximately 7% lower behind the hardware because of photon attenuation. However, as the
radiation beam enters the phantom (or patient) at multiple angles for SABR treatment techniques,
there is no given region in front or behind the metal hardware that can be compared to the above
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results of the Redmond study. From the scatter plots in figures 4.7 and 4.15 for ∆DIC and γ results,
the uncertainties in measurements appear consistent between MattLTi and MattLPVC.
The ability to accurately deliver SABR treatments to the increasing number of patients with metal
hardware in-situ will enable targeted high dose radiotherapy to be given, potentially improving
quality of life and outcomes for this group of patients. The number of people living beyond cancer is
expected to rise rapidly in New Zealand in the coming years due to an aging and growing population
with increased survival rates due to improved diagnosis and treatments [25]. The improved survival
has led to a number of new challenges for cancer services as we continue to see more patients
presenting with previous hospital treatments which may extend to outside the radiation therapy
services [25]. Hence, we anticipate more patients that need SABR spine treatment will have
metal-ware in-situ and this work suggests radiotherapy planned with RayStation would produce
treatment plans appropriate for this cohort of patients. This is of course provided the therapy
margins used for ROI expansion are not reduced.
Compared to film, point dose measurements made with an IC may be less clinically relevant to
assess a SABR spine treatment plan as it is more important to assess if the plan delivered achieves
adequate conformality for treatment. To assess conformality we should look at the dose fall-off from
the high dose region (typically the PTV or spinal vertebrae where the tumour is) to the low dose
region (the spinal cord PRV, at the centre of the spinal vertebrae we are treating). This is best
assessed with film dosimetry as film has high spatial resolution as described in section 3.1.3.
The results of this thesis work suggests that overall, there is a <5% dosimetric equivalence in SABR
spine treatments with and without metal in the vicinity of the treatment region. This 5% uncertainty
is likely to consist of a combination of uncertainties associated with dosimeter calibration, accuracy
of phantom over-ride values, linac dose calibration, beam stability, CT data, measurement setup
inaccuracies and the accuracy of the dose calculation algorithm [92]. At ACH, 12 Gy per fraction is
delivered in spine SABR. A conservative approach is taken to use a 14.5 Gy dose limit to the spinal
PRV (figure 2.19) compared to the SC 24 recommendation of 17 Gy [36]. With a 14.5 Gy dose limit
to the spinal PRV, theoretically the 5% uncertainty translates to potentially a 15.23 Gy (105% of
14.5 Gy) dose to the spinal PRV (as the maximum dose to the spinal cord PRV objective is defined
in the SABR spine treatment planning protocol), which is still well within the 17 Gy dose limit to
the spinal cord outlined in SC24 recommendations [36]. Hence, the implications of treating a patient
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with metal-ware in-situ may be a further 0.725 Gy (5% of 14.5 Gy) to the spinal cord from what is
planned. This additional dose may be acceptably small relative to total dose to this OAR but
ultimately lies in the RO’s clinical judgement and a case by case assessment. Prior to the application
of these results, clinicians should consider the full details of recommendations made from this study,
including its limitations detailed in this section. To overcome these limitations and broaden the
scope and application of this thesis recommendations for future work are described in chapter 6.
Limitations in the Use of MattL for SABR Spine Measurements
In this thesis, MattL’s geometric centre is aligned to the linac treatment unit’s isocentre and
therefore to the region of the spinal cord. This would be useful to assess the conformality of the
treatment in determining if it is sufficient enough for clinical treatment of the patient (e.g. during
PSQA). One of the main limitations of MattL is that it is not capable of performing film
measurements in a plane intersecting the geometric centre of the phantom i.e. the spinal canal which
is a major OAR to consider in treatment planning. This is an unfortunate pit-fall in selecting a rigid
modular structure for the anthropomorphic phantom while incorporating a surrogate for bone
without embedding/surrounding the bone and metal in a solid material. While the initial design of
MattLTi (section 5.1.2) may have allowed film measurements through the spinal canal by halving or
quartering the centre heterogeneous block this was not an option due to problems met while
producing the initial phantom. Ideally a phantom that allows film placement in planes close to the
spinal cord-vertebrae boundary would have been useful to fully understand the impact to the spinal
cord.
As mentioned in section 2.4.3, the placement of the IC in steep dose gradients due to the rigid design
of MattL was at times unavoidable due to the rigid design of MattL. This was noted for each of the
IC measurements with SABR spine treatments applied. From 16 IC measurements made in each
location (8 times per SABR spine patient plan in MattLPVC and MattLTi), 6 out of 16 (38%)
measurements in the anterior IC location were made in steep dose gradients while all measurements
made in the central and lateral IC locations were made in a steep dose gradient. Hence these
measurements were sensitive to setup inaccuracies and partial volume effects which meant these
results were likely to have large uncertainty associated with them and hence there is greater reliance
on the results from film measurements.
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Statistical Methods
The CI gives a range of the largest and smallest effects that are likely from the observed data (8
SABR spine treatment plans used in this study). The CI gives useful information, since narrow CI
ranges rule out effects far from the CI and are usually determined from large study sizes where the
estimate of the effect is quite precise (i.e. the study has a reasonable ‘power’ to detect an effect).
The opposite of this, that wide CIs capture a diverse range of effects is also true.
The bootstrap bias and standard error associated with ion chamber measurements are small in
relation to the confidence interval calculated from the bootstrap resamples (table 4.1). Whereas the
bootstrap bias and standard error for film measurements is larger when compared to the confidence
interval calculated. While the bias does not cause concern, the standard error indicates some spread
in the data and perhaps a less precise estimate of the population. While the bias and standard error
for the bootstrap is not particularly linked to the confidence interval, it gives a quantifiable idea of
the distribution of the bootstrap statistic determined. From figures B.4, B.6 and B.7 this is evident
as the histogram of the bootstrapped statistic shows a positive skew towards the right.
In bootstrapping we temporarily substitute the empirical probability distribution induced by the
sample for the probability distribution defined by the population. Re-sampling with replacement
removes the need to perform tedious calculations with the empirical distribution, required to assess
the initial statistic. For small samples the bootstrap might be less informative than expected and it
might be useful to make additional assumptions [93]. The bootstrap is not a solution that solves all
problems as it does not work well if rare events are missing from the sample, so it does not account
for more subtle biases. Hence, although the bootstrap can be a powerful tool to utilise, caution and
common sense should be used when applying this [93]. As there is no large bias or standard error in
the bootstrapped resamples, it is not evident that the bootstrap deviates significantly from the
original sample. Hence, assuming the sample is a good representation of the population, the
bootstrap resamples, with similar statistics to the original sample, are also representative of the
population. The results from the bootstrap are no more generalised than those from any other
statistical procedure. Ultimately, it is always a challenge to assess if a sample is a good
representation of the population (especially a small sample) unless you have the information about
the population itself [94]. The number of bootstrap samples required should be determined from how
large the variance of the statistic is [94]. In this study’s case, we were not interested in the complete
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distribution of the statistic but in constructing a confidence interval and therefore B=5000 bootstrap
resamples was more than sufficient [94,95].
In this thesis work the percentile interval is used to determine the CI for the TOST, from the
bootstrap resamples. If the distribution of the bootstrap statistic is roughly normal then the
standard normal interval (the alternative method of determining the CI) and the percentile interval
will nearly agree [68]. While the central limit theorem states normality can be assumed for large
sample sizes, for small sample sizes, normality may not be assumed. However, the percentile interval
has good coverage performance of the resampled distribution [68]. An important caveat of using the
percentile method is that it is calculated with no knowledge of the underlying normal distribution as
instead, an empirical distribution is used that may underestimate the tails or extremes of the
distribution [68]. More advanced bootstrap intervals described in Efron [68] partially correct for this




The outcomes of this study will help quantify the potential disparity between the RayStation TPS
and the dose delivered on the treatment unit. Given more time or accessibility to resources further
work could be achieved to reform the results of this research and refine the use of MattL. This may
require a multidisciplinary approach. This section discusses future work that may be valuable to add
to the results of this thesis to guide clinicians in the treatment of SABR spine patients with metal
implants in-situ.
6.1 Additional Work Prior to Clinical Implementation
Bootstrapping is one method to assess a statistic computed from a sample. As discussed in section
5.2, the main assumption in applying the bootstrap is that the sample is randomly selected from the
population and therefore is an accurate representation of the population. This depends on the
statistic of interest and some properties of the population distribution. For example, the bootstrap
works for sampling means with population distributions that have finite variance but not when they
have infinite variance and will not work for estimating extremes, regardless of the population
distribution. The final precision of the bootstrap statistic is determined by the size of the original
sample size, and does not depend on the number of bootstrap resamples taken, B. For extremely
small sample sizes (e.g. <4), the number of distinct bootstrap samples is large as the bootstrap
resamples are not rich enough, however this is not a particular issue for sample sizes as large as
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eight [67,94]. Therefore, for small samples, the bootstrap may be less informative and to improve
the study, and the reliability of the bootstrap, additional measurements should be considered, given
additional resources (GAFchromic EBT3 film) to carry out measurements. This would ensure that
the sample used for the bootstrap is a true representation of the population.
A set-up inaccuracy study was not conducted in this thesis work due to limitations on film available
for use. Prior to clinical implementation of these results or MattL for PSQA, a study on the
reproducibility should be conducted to establish setup inaccuracies or uncertainties. While in this
thesis an estimation of the uncertainty was performed, based on the validation of MattL the setup
uncertainty should be investigated further to commission MattL as a PSQA device.
6.2 Monte Carlo
Monte Carlo (MC) simulations, considered a gold standard for dose calculations, considers all the
physical processes involved with photon interactions with matter in general and human tissues in
particular [96]. The use of MC is an ideal tool to investigate how dose is deposited in and around
metal hardware. MC accounts for lateral electron transport which CCC based TPS do not take into
account particularly well [97]. Through MC, a more complete evaluation of radiation dose to
structures of concern (i.e. the spinal cord) may help guide SABR spine treatment design with
metal-ware in-situ [24,32,98]. For example, selection of beam angles and weightings for optimal
coverage, as well as ensuring the actual dose, delivered to critical structures, is limited by
considering that electron back-scatter from high density metal hardware may lead to an
underestimation of dose in the TPS [24,30].
Initially, this researcher was hoping to utilise RayStation v8B’s new MC dose calculation algorithm
to compare both the CCC and MC calculated dose distribution to that measured. However, this was
not available at ACH. Access to a workstation with a Monaco TPS that uses MC dose calculation
was also investigated however this was not clinically commissioned to interface and connect to the
treatment machines at ACH. Therefore dose measurements from treatment plans generated in
Monaco could not be performed for this thesis work. However, when RayStation’s MC dose
algorithm or another clinical TPS with a MC based algorithm becomes available at ACH, it would
be useful to compare the dose calculated with MC simulation to the RayStation CCC calculated
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dose and measurements.
6.3 Three-Dimensional Printing
Patient specific dosimetric phantoms that utilise 3D printing (3DP) manufactured for clinical use are
available for purchase commercially. 3DP materials improve the accuracy of patient specific QA as
they provide accurate geometric and dosimetric representation of the individual patient. While this
commercial service is not used at ACH, future work to improve the design of the anthropomorphic
phantom may require the use of 3DP to closely match the body tissues in shape and size (e.g. the
shape of the vertebral bone). Validation of the physical and radiological properties of 3DP materials
would be required prior to their use in radiation therapy treatments processes like PSQA.
6.4 Further Flexibility in Measurements Location
The modular design of the phantom facilitates a robust and reproducible IC and film placement,
however this limits the position of the film measurements as discussed in section 5.2. Ideally, film
measurements crossing isocentre and IC point dose measurements anywhere in the field would be
preferred, however this was not achievable in the design of the phantom as the metal implants
needed to be incorporated in it. Given more time and resources, improvements to MattL to allow
film placement through the isocentre of MattL should be investigated. This may be facilitated
sectioning the central removable block into halves or quarters. While this is simple for the central
removable block in MattLperspex and MattLPVC, for the central removable block (the water-box
block used in MattLTi) a redesign will be necessary. Consideration of engineering challenges for any
redesign should be considered as the current design of MattL, presented in this thesis, required over
a year to manufacture.
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6.5 Modern CT Scanners
The Siemens scanner used to create the virtual model of MattL in RayStation did not have any
metal artifact reduction (MAR) capabilities. Hence density over-ride values were selected for use in
the model of MattL in RayStation. Ideally, a CT scanner, with an extended CT HU to electron
density scale, spectral CT to help identify actual densities of material as well as MAR capabilities
should be used to create the model of MattL to reduce potential systematic errors introduced by the
application of a density over-ride due to metal artefacts [49]. The dose calculated in the TPS may
not be accurate as the HU of tissues may be effected by photo-starvation effects [49] or metal streak
artifacts [92] introduced from high atomic density (Z) materials. While the scanner may improve the
virtual model of MattL, an evaluation of the effectiveness of the CT scanner’s MAR capabilities
should be conducted to assess if the MAR is adequate to forego the use of material density over-rides.
6.6 Precise Measurement of Density Over-ride Values
The density over-ride values chosen in the thesis were based on knowledge of the material and were
validated as described in sections 3.1.5 and 3.2.2. Due to commercial sensitivity, the full details of
the chemical composition of titanium implants, which were kindly donated from Pioneer Medical,
and therefore the electron density of this was not available. Likewise, the electron density of PVC
and perspex material used to create MattL was not available and these materials, sourced through
clinical engineering were likely to have impurities or inconsistencies throughout the material due to
the manufacturing process of these. While this thesis work used IC measurements to investigate the
transmission through each material and validate the density over-ride based on knowledge of the
material, other methods could be investigated to guide the selection of a sensible density over-ride
value in future work. These may include theoretical derivations, measurements with a dual energy
x-ray CT, NMR spectroscopy, γ ray or electron diffraction to determine the elemental composition of
the material [99, 100].
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6.7 Other Energies
The SABR spine treatment is restricted to photon beam energies below 6 MV as lateral charged
particle equilibrium (LCPE) needs to be established for the small fields used in this technique. Lack
of LCPE is one of the challenges for small fields [21]. LCPE is lost if the beam half width (i.e.
radius, r) is smaller than the maximum range of secondary electrons that contribute dosimetrically
to the absorbed dose. Hence for a 6 MV beam, LCPE is lost as field size decreases from
approximately 2 cm (beam half width or r= 1cm) 6.1 [21]. For higher energies, e.g 10 MV LCPE is
lost as the field size decreases from approximately 3 cm beam width (r= 1.5 cm). Hence, as small
fields, down to <3 cm beam width are used in the SABR spine technique, LCPE can only be
established in 6 MV photon beams or lower and is lost if higher beam energies are utilised.
Figure 6.1: Ratios of dose-to-water to water-collision-kerma calculated by Monte Carlo simu-
lation in water at 5 cm depth on the central axis of high energy photon beams. The data are
plotted as a function of the radius of clinical narrow beams defined at 100 cm SSD for the high
energy X-ray beams and 80 cm SS for Co-60. Taken from [21]
We would expect a greater difference in the types of photon interactions that dominate at high
radiotherapy beam energies as explained in section 2.1.1 and depicted in figure 2.7 [92]. However
given only photon beam energies of 6 MV or less are utilised in spine SABR treatments due to loss
of LCPE at other energies, the discrepancy between CCC-based TPS and dose delivered on the
treatment unit (investigated through measurements, MC or other means) are not of interest for spine
SABR treatments. Hence, there is no need to investigate the effects of metal on the accuracy of dose
calculated from SABR spine treatment plans in RayStation using higher beam energies.
Chapter 7
Conclusion
In this thesis, a phantom was made, data were acquired and analysis was performed using a TOST
analysis on bootstrapped data to investigate if SABR spine patients with metal-ware near the
treatment region can be safely treated at ACH. This examined if the accuracy of RayStation to
calculated dose for SABR spine treatment plans with metal-ware in the treatment region was
equivalent to when there is no metal-ware.
The first part of this research was the development of an anthropomorphic phantom called MattL.
MattL was created to facilitate dose measurements with a 0.04cc ionisation chamber and film to
assess dose delivered from SABR spine treatment plans with and without metal. This was a major
undertaking on its own as it required not only careful selection of materials but the design and
testing of the phantom’s efficacy for dose measurements. Validation of MattL was necessary for the
next part of this thesis, to investigate the accuracy of RayStation in determining the dose through
metal for SABR spine treatments through dose measurements.
Metal implants are becoming increasingly common in radiotherapy patients as treatments improve
patient lifespan and more patients are having further treatment post-surgery. Therefore
understanding modelling in metal is very important. While MattL has been validated for use to
investigate SABR spine treatment plans in this work, it has been earmarked for further use in other
aspects of the radiotherapy process at ACH including the commissioning of a new CT scanner,




Overall, based on the TOST analysis performed, SABR spine treatments with metal-ware in-situ are
equivalent to spine SABR treatments without metal-ware to within ±5% uncertainty (±3%
uncertainty for IC measurements). Additional measurements of SABR spine treatment plans should
be analysed to ensure the sample data is an accurate representation of SABR spine patients.
Appendix A
Phantom Design and Validation
A.1 Ionisation Chamber Absolute Dose Measurements
Beam Dose rate Electrometer Average ks kpol



























Table A.1: Measurements made following IAEA TRS 398 protocols to determine ks and kpol at
varying dose rates for 6 MV FFF and flat beam energies.
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A.2 Determination of Density Over-Ride Value










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SABR Spine Plan Measurements
B.1 Dose Measurements
B.1.1 Ionisation Chamber Measurements
Point Dose in MattLPVC phantom (Gy)
RayStation Calculation PVC Measurement ∆DIC MattLPVC (%)
IC location IC location IC location
Patient Centre Anterior Lateral Centre Anterior Lateral Centre Anterior Lateral
1 5.80 5.99 7.81 6.08 5.69 7.09 -4.67% 5.31% 10.23%
2 5.04 15.13 7.34 5.01 15.10 7.08 0.65% 0.22% 3.61%
3 4.83 9.39 4.87 5.19 9.26 4.90 -6.87% 1.40% -0.68%
4 3.48 10.9 4.9 3.54 10.55 4.74 -1.59% 3.36% 3.39%
5 4.26 11.76 4.83 4.15 11.56 5.13 2.65% 1.74% -5.92%
6 2.76 12.54 5.97 2.67 12.29 5.92 3.40% 2.04% 0.88%
7 3.70 10.08 6.24 4.08 9.68 6.23 -9.25% 4.15% 0.13%
8 4.46 10.68 6.71 4.29 10.55 7.16 3.86% 1.23% -6.33%
Table B.1: Ionisation chamber measurements of SABR spine plans in MattLPVC. The ∆DIC
was determined according to equation 4.1.
112
B.1. Dose Measurements 113
Point Dose in MattLTi phantom (Gy)
RayStation Calculation Matt L Measurement ∆DIC MattLTi (%)
IC location IC location IC location
Patient Centre Anterior Lateral Centre Anterior Lateral Centre Anterior Lateral
1 5.82 6.04 7.74 5.99 5.72 6.86 -2.84% 5.59% 12.83%
2 5.07 15.08 7.63 4.94 15.24 7.38 2.63% -1.05% 3.39%
3 4.9 9.38 5.12 5.13 9.16 4.97 -4.48% 2.40% 3.02%
4 3.56 11.02 5.07 3.60 10.59 4.85 -1.11% 4.06% 4.54%
5 4.33 11.8 5.23 4.38 11.58 5.32 -1.14% 1.90% -1.69%
6 2.76 12.54 5.97 2.74 12.22 6.22 0.73% 2.62% -4.02%
7 3.76 9.89 6.5 4.03 9.70 6.28 -6.70% 1.96% 3.50%
8 4.46 10.68 6.71 4.17 10.49 7.22 6.95% 1.81% -7.06%
Table B.2: Ionisation chamber measurements of SABR spine plans in MattLTi. The ∆DIC was
determined according to equation 4.1.
B.1.2 Film Measurements
Gamma Values in MattLPVC(%) Gamma Values in MattLTi(%)
Film location: Film location:
Posterior Lateral Posterior Lateral
Patient 2%/2mm 3%/1mm 2%/2mm 3%/1mm 2%/2mm 3%/1mm 2%/2mm 3%/1mm
1 87.60 88.00 95.40 90.70 93.60 89.10 97.40 93.90
2 97.20 97.10 93.60 87.30 90.90 90.90 82.00 72.30
3 95.40 90.20 94.90 85.80 95.70 90.10 95.50 93.90
4 97.30 87.70 99.20 87.30 94.30 84.90 97.60 87.10
5 92.80 87.60 93.90 84.30 89.00 79.10 95.70 85.00
6 81.00 70.50 95.60 95.40 95.10 89.80 94.10 94.90
7 96.90 95.00 86.70 74.60 98.10 95.60 83.80 78.70
8 84.60 77.20 93.20 90.60 81.00 72.50 97.10 91.90
Table B.3: Gamma values for comparing film absolute dose measurements of SABR spine plans
in MattLPVC and MattLTi to dose distributioncalculated in RayStation.
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Difference in Gamma Values (%)
Film location:
Posterior Lateral
Patient 2%/2mm 3%/1mm 2%/2mm 3%/1mm
1 6.00 1.10 2.00 3.20
2 -6.30 -6.20 -11.60 -15.00
3 0.30 -0.10 0.60 8.10
4 -3.00 -2.80 -1.60 -0.20
5 -3.80 -8.50 1.80 0.70
6 14.10 19.30 -1.50 -0.50
7 1.20 0.60 -2.90 4.10
8 -3.60 -4.70 3.90 1.30
Table B.4: Difference in gamma value for film absolute dose measurement comparison to Raysta-
tion calculated dose of SABR spine plans of MattLPVC from MattLTi (table B.3). The difference
in gamma values was determined according to equation 4.2.
B.2 Statistical Analysis








{r setup , include=FALSE}
knitr::opts_chunk$set(echo = TRUE)
install.packages("pacman")
pacman ::p_load(here , tidyverse , equivalence , sjstats , car , dplyr , boot ,
reshape2, TOSTER)
#load data into tables
#read data from csv
raw_data <- read_csv(here::here("Rdata.csv")
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)
#input into tables
PVC <- raw_data %>%
filter(phantom == ’MattL_PVC’)
MattL <- raw_data %>%
filter(phantom == ’MattL_Ti’)
#Firstly , look at the spread of data using a scatterplot
# Convert to long format




# Segment into ic and film measurements for seperate graphs
ic_long <- raw_long %>%
filter(measurement %in% c("ic_centre", "ic_ap", "ic_lat")
)
film_long <- raw_long %>%
filter(measurement %in% c("film2pct2mm_ap", "film3pct1mm_ap",
"film2pct2mm_lat", "film3pct1mm_lat")
)
# Add dummy variable for phantom type
ic_long_gg <- ic_long %>%
mutate("phantom_dummy" = case_when(phantom =="PVC" ~ 1,
phantom =="MattL" ~ 0)
)
film_long_gg <- film_long %>%
116 Appendix B. SABR Spine Plan Measurements
mutate("phantom_dummy" = case_when(phantom =="PVC" ~ 1,
phantom =="MattL" ~ 0)
)
#scatter plot for ic measurements with overlaid boxplot
ggplot(ic_long_gg ,
aes(x = phantom ,
value ,
shape = phantom ,









position = position_jitter(w = 0.03,
h = 0)) +
ylab("%Difference (TPS calculation vs. measured dose)") +
ggtitle(’Ion Chamber Measurements in MattL’) +
scale_color_manual(values=c(’black ’,’black ’)) +
scale_fill_discrete(name= "IC position",





#Pr >0.5 no evidence vars are diff
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#scatter plot for film measurements with overlaid boxplot
ggplot(film_long_gg ,
aes(x = phantom ,
value ,
shape = phantom ,









position = position_jitter(w = 0.03,
h = 0)) +
ylab("Gamma Value (%)") +
ggtitle(’Film Measurements in MattL’) +
scale_color_manual(values=c(’black ’,’black ’)) +
scale_fill_discrete(name= "Gamma Criteria , Film position",
labels= c("2%/2m, posterior ", "2%/2mm , lateral",





#Calc difference in measurements (MattL_Ti - MattL_PVC)
#(i.e. negative value indicates MattL %difference is lower PVC)
#merge MattL_Ti and MattL_PVC results into one table
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all.x = TRUE ,
all.y=TRUE
)
#Calculate difference (x-y = MattL_Ti-MattL_PVC)









#Perform the bootstrap and get the confidence interval
#This is for the IC measurements at the central location.
#set arbitrary seed value for replication later if needed
set.seed(43)
#statistical function of interest (the mean) to be passed into "boot ()"
bts_ic_centre <- function(d,i){
d2<-d[i,] #collects samples in boot
return(mean(d2$diff_ic_centre ))
}
# carry out bootstrap for 5000 resamples
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#Repeat for IC measurement at anterior location
#ic_ap
bts_ic_ap <- function(d,i){






# Run test WITH BOOTSTRAP for distribution of paired differences
print("ic_ap")










#Repeat for IC measurement at lateral location
#ic_lat
bts_ic_lat <- function(d,i){




# Run test WITH BOOTSTRAP for distribution of paired differences
print("ic_lat")










#Repeat for film measurement at posterior location with 2%/2mm gamma criteria
#film 2pct2mm ap
bts_film2pct2mm_ap <- function(d,i){
#collect samples in boot
d2<-d[i,]
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return(mean(d2$diff_film2pct2mm_ap))
}
# Run test WITH BOOTSTRAP for distribution of paired differences
print("film 2pct 2mm ap")










#Repeat for film measurement at posterior location with 3%/1mm gamma criteria
#film 3pct1mm ap
bts_film3pct1mm_ap <- function(d,i){




# Run test WITH BOOTSTRAP for distribution of paired differences
print("film 3pct 1mm ap")
boot_mmt <- boot(diff_mmt ,
bts_film3pct1mm_ap ,
R=5000








#Repeat for film measurement at lateral location with 2%/2mm gamma criteria
#film 2pct2mm lat
bts_film2pct2mm_lat <- function(d,i){




# Run test WITH BOOTSTRAP for distribution of paired differences
print("film 2pct 2mm lat")










#Repeat for film measurement at lateral location with 3%/1mm gamma criteria
#film 3pct1mm lat
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bts_film3pct1mm_lat <- function(d,i){




# Run test WITH BOOTSTRAP for distribution of paired differences
print("film 3pct 1mm lat")










#Additional box - plots to display & discuss
#Do IC measurement in central location first
#reformat data for boxplot
index <- 1:8





#paired boxplot with linked pairs
ggpubr :: ggpaired(comb_ic_index ,









ylab="%Difference (TPS calculation vs. measured dose)",
title="Deviation of dose measurement to RayStation
dose estimate \n(Central IC position)"
) +
theme(plot.title = element_text(hjust = 0.5)
)
#Paired boxplot for IC measurement in anterior location
#reformat data for boxplot




#paired boxplot with linked pairs
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xlab= "Phantom",
ylab="%% Difference (TPS calculation vs. measured dose)",
title="Deviation of dose measurement to RayStation
dose estimate \n(Anterior IC position)"
) +
theme(plot.title = element_text(hjust = 0.5))
#Paired boxplot for IC measurement in lateral location
#reformat data for boxplot





#paired boxplot with linked pairs









ylab="%Difference (TPS calculation vs. measured dose)",
title="Deviation of dose measurement to RayStation
dose estimate \n(Lateral IC position)"
) +
theme(plot.title = element_text(hjust = 0.5))
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#Paired boxplot for film measurement in posterior location
#gamma criteria 3%/1mm
#reformat data for boxplot




#paired boxplot with linked pairs










title="Deviation of dose measurement to RayStation
dose estimate \n(Gamma 3%/1mm with Gafchromic film
in posterior position)"
) +
theme(plot.title = element_text(hjust = 0.5))
#Paired boxplot for film measurement in posterior location
#gamma criteria 2%/2mm
#reformat data for boxplot
comb_film_index <- cbind(comb %>%
rename(MattL_PVC=film3pct1mm_ap.x,
MattL_Ti=film3pct1mm_ap.y),
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index)
#paired boxplot with linked pairs










title="Deviation of dose measurement to RayStation
dose estimate \n(Gamma 2%/2mm with GafChromic film
in posterior position)"
) +
theme(plot.title = element_text(hjust = 0.5))
#Paired boxplot for film measurement in lateral location
#gamma criteria 3%/1mm
#reformat data for boxplot




#paired boxplot with linked pairs
ggpubr :: ggpaired(comb_film_index ,
cond1 = "MattL_PVC",
cond2="MattL_Ti",








title="Deviation of dose measurement to RayStation
dose estimate \n(Gamma 3%/1mm with Gafchromic film
in lateral position)"
) +
theme(plot.title = element_text(hjust = 0.5))
#Paired boxplot for film measurement in lateral location
#gamma criteria 2%/2mm
#reformat data for boxplot




#paired boxplot with linked pairs
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ylab="Gamma (%)",
title="Deviation of dose measurement to RayStation
dose estimate \n(Gamma 2%/2mm with GafChromic film
in lateral position)"
) +
theme(plot.title = element_text(hjust = 0.5))
#Use ggplot for Pearson correlation test with R and p values with error bars
library("ggpubr")
#add in columns for error bars
comb_ic <- comb_ic %>%
mutate(’upper_error_x’ = value.x+3) %>%
mutate(’lower_error_x’ = value.x-3) %>%
mutate(’upper_error_y’ = value.y+3) %>%
mutate(’lower_error_y’ = value.y-3)
#film
comb_film <- comb_film %>%
mutate(’upper_error_x’ = value.x+3) %>%
mutate(’lower_error_x’ = value.x-3) %>%
mutate(’upper_error_y’ = value.y+3) %>%
mutate(’lower_error_y’ = value.y-3)





conf.int = FALSE ,
cor.coef = TRUE ,
cor.method = "pearson",
xlab = "MattL_PVC %Difference (%)",
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ylab = "MattL_Ti %Difference (%)",












conf.int = FALSE ,
cor.coef = TRUE ,
cor.method = "pearson",
xlab = "MattL_PVC Gamma Value (%)",
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B.2.2 Bootstrapped Samples
Deviations in Ionisation Chamber Measurements
Figure B.1: Histogram and quantile-quantile of bootstrapped samples of the measurement
deviation from RayStation calculated dose for ionisation chamber measurements in the central
location.
Figure B.2: Histogram and quantile-quantile of bootstrapped samples of the measurement
deviation from RayStation calculated dose for ionisation chamber measurements in the anterior
location.
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Figure B.3: Histogram and quantile-quantile of bootstrapped samples of the measurement
deviation from RayStation calculated dose for ionisation chamber measurements in the lateral
location.
Deviations in Film Measurements
Figure B.4: Histogram and quantile-quantile of bootstrapped samples of the measurement
deviation from RayStation calculated dose for film measurements in the posterior location with
a 2%/2mm gamma criteria.
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Figure B.5: Histogram and quantile-quantile of bootstrapped samples of the measurement
deviation from RayStation calculated dose for film measurements in the lateral location with a
2%/2mm gamma criteria.
Figure B.6: Histogram and quantile-quantile of bootstrapped samples of the measurement
deviation from RayStation calculated dose for film measurements in the posterior location with
a 3%/1mm gamma criteria.
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Figure B.7: Histogram and quantile-quantile plot of bootstrapped samples of the measurement
deviation from RayStation calculated dose for film measurements in the lateral location with a
3%/1mm gamma criteria.
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[91] T. Knöös, B. McClean, A. Ahnesjö, M. M. Aspradakis, C. Ceberg, and N. Jornet, ESTRO -
Dose Modelling and Verification for External Beam Radiotherapy. 2019.
[92] N. Papanikolaou, J. Battista, A. Boyer, C. Kappas, E. Klein, T. Mackie, M. Sharpe, and
J. Van Dyk, “AAPM TG 65 report 85 - tissue inhomogeneity corrections for megavoltage
photon beams,” 2004.
[93] L. Kogan, “Lecture 9 small-sample inference and bootstrap,” 2010.
[94] M. Chernick, Bootstrap Methods: A Guide for Practitioners and Researchers, Second Edition.
01 2008.
BIBLIOGRAPHY 143
[95] R. Wilcox, Fundamentals of Modern Statistical Methods: Substantially Improving Power and
Accuracy. Springer New York, 2010.
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